[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 861
6. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Piketty M, Barranger E, Najat M, François P, Daraï E: Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix. Am J Obstet Gynecol; 2005 Oct;193(4):1382-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix.
  • Radical trachelectomy is an effective fertility-sparing treatment for women with early-stage cervical cancer.
  • We describe the first reported ovarian recurrence after radical trachelectomy for stage IB1 adenocarcinoma cervical cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Cervix Uteri / surgery. Neoplasms, Second Primary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery. Uterus / surgery


8. Cabrera S, Franco-Camps S, García A, Vergés R, Díaz-Feijoo B, Pérez-Benavente MA, Poza JL, Bradbury M, Xercavins J, Gil-Moreno A: Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus. Arch Gynecol Obstet; 2010 Jul;282(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus.
  • PURPOSE: The association between cervical cancer and uterine prolapse is rare and sparsely represented in literature, despite the high incidence of the latter.
  • METHODS: We report a case of cervical cancer in prolapsed uterus treated with radical hysterectomy performed totally by laparoscopic approach, and review other case reports published about this clinical condition.
  • RESULTS: We present the first case reported in literature in our knowledge of cervical cancer in prolapsed uterus treated with radical hysterectomy performed totally by laparoscopic approach.
  • CONCLUSIONS: Radical hysterectomy can be correctly performed totally by laparoscopic approach even when cervical cancer is associated with severe uterine prolapse.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / surgery. Uterine Prolapse / surgery


9. Karlsson S, Olsson B, Klinga-Levan K: Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model. Cancer Cell Int; 2009;9:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model.
  • BACKGROUND: In the Western world, endometrial cancers are the most common gynaecological neoplastic disorders among women.
  • The objective of this work was to identify a gene expression signature specific for endometrial adenocarcinomas to be used for testing potential endometrial biomarkers.
  • RESULTS: Changes in expression between endometrial adenocarcinomas and non-/pre-malignant endometrium from the BDII EAC rat model were compared in cDNA microarray assays.
  • CONCLUSION: Taken together, we present a unique data set of genes with different expression patterns between EACs and non-/pre-malignant endometrium, and specifically we found three genes that were confirmed in two independent analyses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jan;38(1):95-104 [17673689.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):657-67 [11522750.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Aug;177(1):43-50 [17693190.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4794-802 [17150964.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):427-33 [15993480.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):137-41 [15796960.001]
  • [Cites] Semin Reprod Endocrinol. 1999;17(1):73-92 [10406078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):411-7 [8781735.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2479-81 [15073010.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003 [12186655.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2778-90 [12019154.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):795-9 [11745480.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • (PMID = 19426485.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2687412
  •  go-up   go-down


10. Yoshida M, Watanabe G, Shirota M, Maekawa A, Taya K: Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev; 2005 Dec;51(6):707-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
  • Ovarian dysfunction leading to hormonal imbalance plays a crucial role in uterine carcinogenesis in rats as well as women.
  • However, the effects of a reduction in primordial follicles at birth on uterine adenocarcinoma development have hitherto not been determined.
  • The present study was therefore conducted using female Donryu rats, a high incidence rat strain of uterine adenocarcinoma.
  • The incidence of uterine adenocarcinomas and multiplicity of uterine neoplastic lesions were significantly increased by the 5.0 mg/kg, but not the 2.5 mg/kg busulfan treatment.
  • These results provide evidence that the reduction of primordial follicles promotes uterine adenocarcinoma development in rats in association with an earlier occurrence of the persistent estrus status.
  • [MeSH-major] Adenocarcinoma / etiology. Antineoplastic Agents, Alkylating / pharmacology. Busulfan / pharmacology. Endometrial Neoplasms / etiology. Ovarian Diseases / chemically induced. Ovarian Follicle / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177545.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Gonadal Steroid Hormones; G1LN9045DK / Busulfan
  •  go-up   go-down


16. Temkin SM, Pezzullo JC, Hellmann M, Lee YC, Abulafia O: Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol; 2007 Feb;30(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is body mass index an independent risk factor of survival among patients with endometrial cancer?
  • OBJECTIVE: To evaluate whether body mass index (BMI) is an independent risk factor for survival in patients with endometrial adenocarcinoma.
  • METHODS: Women treated for endometrial cancer at the State University of New York (SUNY), Downstate and Kings County Hospital between January 1982 and September 2003 were eligible.
  • Patients were divided into groups based upon their histology at the time of diagnosis.
  • The first included patients with low-grade endometrioid adenocarcinoma (FIGO grades 1 and 2); the second included grade 3 endometrioid adenocarcinoma; and the third contained papillary serous and clear cell carcinomas.
  • There were 312 patients (70%) treated for low-grade endometrial adenocarcinoma; 64 patients (14%) for grade 3 endometrioid adenocarcinoma; and 71 patients (16%) for papillary serous and clear cell adenocarcinoma.
  • BMI was also correlated to tumor grade, stage at diagnosis, age, and race.
  • Statistical analyses revealed the majority of the association between BMI and survival can be attributed to the association between BMI and these other risk factors for survival in endometrial cancer.
  • CONCLUSIONS: Increased BMI is associated with survival advantage among patients with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / physiopathology. Body Mass Index. Endometrial Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278888.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wang J, Chung MH, Xue B, Ma H, Ma C, Hattori M: Estrogenic and antiestrogenic activities of phloridzin. Biol Pharm Bull; 2010;33(4):592-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Light increase of the uterine weight and serum estradiol content of mouse was observed when the glucoside was administered orally for 7 d.
  • After oral administration, phloridzin was found mainly in the blood and a small part was metabolized to phloretin.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / therapeutic use. Cell Line, Tumor. Cell Proliferation / drug effects. Estradiol / metabolism. Estrogens / pharmacology. Estrogens / therapeutic use. Fagaceae / chemistry. Female. Glucosides / pharmacology. Glucosides / therapeutic use. Humans. Mice. Mice, Inbred Strains. Organ Size. Phytotherapy. Tissue Distribution. Uterus / metabolism. Yeasts. beta-Galactosidase / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20410591.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Estrogen Receptor Modulators; 0 / Estrogens; 0 / Glucosides; 0 / Phytoestrogens; 0 / Plant Extracts; 0 / Receptors, Estrogen; 4TI98Z838E / Estradiol; CU9S17279X / Phlorhizin; EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


18. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer; 2006 Aug 15;107(4):746-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
  • BACKGROUND: Endometrial cancer is a common gynecologic malignancy among women.
  • The molecular mechanisms involved in the progression of endometrial cancer are unclear, which has hampered the development of an effective treatment.
  • METHODS: Survivin mRNA and protein expression levels were analyzed in human normal cycling endometrium, atypical endometrium, and endometrial adenocarcinoma by immunohistochemical, reverse-transcriptase polymerase chain reaction (RT-PCR), and Western blot analyses.
  • To study the biological function of survivin in endometrial cancer, RNA interference was applied to knock down survivin expression in the Ishikawa endometrial cancer cell line by recombinant plasmids producing survivin small hairpin RNA.
  • RESULTS: Higher levels of survivin mRNA and protein expression were observed in endometrial adenocarcinomas than in atypical or normal endometrium.
  • Immunohistochemical staining revealed that 83.3% (50 of 60) of endometrial adenocarcinoma samples, 55.0% (11 of 20) of atypical endometrium samples, and 25.0% (5 of 20) of normal endometrium samples were positive for survivin protein.
  • Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) upregulated survivin protein expression by activating the MAPK pathway in endometrial cancer cells.
  • CONCLUSIONS: Survivin is an attractive target for endometrial cancer treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cell Proliferation. Endometrial Neoplasms / pathology. Microtubule-Associated Proteins / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826583.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


19. Halabalaki M, Alexi X, Aligiannis N, Lambrinidis G, Pratsinis H, Florentin I, Mitakou S, Mikros E, Skaltsounis AL, Alexis MN: Estrogenic activity of isoflavonoids from Onobrychis ebenoides. Planta Med; 2006 May;72(6):488-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 1 - 4 induced cell proliferation and gene expression in breast and endometrial cancer cells in an ER-dependent manner.
  • While the antiestrogen ICI 182,780 could inhibit the induction of proliferation of ER-positive breast cancer cells by 1-4, it could not prevent 1 from exhibiting significant ER-independent cytotoxicity at 10 microM.
  • By contrast, 1 was much less cytotoxic and only weakly estrogenic for ER-positive endometrial adenocarcinoma cells.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773531.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Isoflavones; 0 / Phytoestrogens; 0 / Plant Extracts
  •  go-up   go-down


20. Stewart CJ, Little L: Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology; 2009 Jul;55(1):91-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition.
  • AIMS: Endometrial endometrioid adenocarcinomas (EEC) may show a distinctive morphological alteration characterized by the presence of microcystic, elongated and fragmented ('MELF') glands.
  • These changes share features of epithelial-mesenchymal transition (EMT) in carcinomas arising at other sites.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Differentiation. Endometrial Neoplasms / pathology. Epithelial Cells / pathology. Immunophenotyping. Mesoderm / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614771.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Keratin-7; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


21. Obokata A, Watanabe J, Nishimura Y, Arai T, Kawaguchi M, Kuramoto H: Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium. Anticancer Res; 2007 Jan-Feb;27(1A):95-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
  • This study aimed to examine the expressions of MMP-7 and -11 and TIMP-1 in normal, hyperplastic and neoplastic endometrium and their correlation to clinicopathologic factors.
  • PATIENTS AND METHODS: Tissue samples of 40 normal endometria, 20 endometrial hyperplasias and 120 endometrial endometrioid adenocarcinomas were used for the study.
  • MMP-7 was expressed at significantly higher levels in endometrial hyperplasia than normal endometrium, whereas MMP-11 was expressed at lower levels.
  • In endometrial adenocarcinoma, MMP-7, MMP-11 and TIMP-1 were expressed at the same levels as in hyperplasia.
  • MMP-7 expression in endometrial carcinoma was correlated with myometrial invasion and estrogen receptor expression.
  • CONCLUSION: MMP-7, MMP-11 and TIMP-1 expression may be regulated by the menstrual cycle, and related to the degradation and remodeling of the normal endometrium.
  • MMP-7 expression might be a prognostic factor in endometrial carcinoma.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 11 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / metabolism. Cytoplasm / enzymology. Cytoplasm / metabolism. Endometrium / enzymology. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352221.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


22. Hidaka T, Nakamura T, Shima T, Yuki H, Saito S: Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res; 2006 Jun;32(3):330-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
  • AIM: There is no standard chemotherapy regimen for patients with advanced endometrial adenocarcinoma.
  • METHODS: Twenty-eight patients who underwent surgery and had histologically confirmed advanced endometrial adenocarcinoma, International Federation of Gynecology and Obstetrics stage III/IV, received combination chemotherapy.
  • National Cancer Institute Common Toxicity Criteria grade 3-4 thrombocytopenia and gastrointestinal toxicities occurred significantly less frequently in the paclitaxel/carboplatin group (0% and 16.7%) than in the CAP group (31.3% and 68.8%) (P = 0.0389 and P = 0.0062).
  • CONCLUSIONS: We conclude that paclitaxel/carboplatin is a promising regimen which could be substituted for CAP, with major activity and a highly acceptable toxicity profile for the treatment of advanced endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764625.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Huang SY, Jung SM, Ng KK, Chang YC, Lai CH: Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol; 2005 May;97(2):652-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
  • BACKGROUND: There have been several reports about successful fertility-preserving treatment of endometrial carcinoma with subsequent pregnancy.
  • However, conservative hormonal treatment for early-stage endometrial cancer still entails some risk.
  • CASE: We present a 36-year-old nulliparous woman, initially diagnosed as clinical stage IA, grade 1 endometrial adenocarcinoma, receiving 6-month conservative treatment with remission achieved at 4 months from diagnosis.
  • Recurrence at the endometrium was documented at the end of treatment.
  • The final pathology revealed well-differentiated endometrioid adenocarcinoma with inner one-third myometrial invasion and right ovarian metastasis.
  • CONCLUSION: This case report signals a warning that negative preoperative imaging studies are not reassuring for a relapsing low-grade, early-stage endometrial carcinoma failing conservative treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Megestrol Acetate / therapeutic use. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863173.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


2
Advertisement
4. Ibáñez Pinto A, Fernández Salgado E, Castro Ortiz E, Baltar Arias R, Vázquez Vázquez S, Ledo Barro L, Vázquez San Luis J, Vázquez Astray E: [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy]. Gastroenterol Hepatol; 2007 Nov;30(9):530-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
  • [Transliterated title] Hemorragia digestiva de origen incierto por un adenocarcinoma endometrial metastásico. Respuesta al tratamiento hormonal.
  • BACKGROUND: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • A computed tomography scan showed extensive lymphatic, abdominal and pelvic recurrence of the cancer.
  • Control of bleeding and a 22-month survival were obtained after treatment with oral medroxyprogesterone acetate.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Gastrointestinal Hemorrhage / etiology. Medroxyprogesterone Acetate / therapeutic use. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / secondary. Retroperitoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980130.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Number-of-references] 19
  •  go-up   go-down


25. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M: Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res; 2008 Nov 15;14(22):7367-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.
  • PURPOSE: Endometrial cancer is the most common gynecologic malignancy.
  • In addition, the efficacy of EMP2 diabodies on endometrial cancer tumors was determined using mouse xenograft models.
  • RESULTS: Treatment of human endometrial adenocarcinoma cell lines with anti-EMP2 diabodies induced significant cell death and caspase-3 cleavage in vitro.
  • CONCLUSIONS: These findings suggest that EMP2 may be a potential pharmacologic target for human endometrial cancer.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Aug 24;106(4):403-11 [11525727.001]
  • [Cites] Dev Biol. 2006 Apr 15;292(2):430-41 [16487956.001]
  • [Cites] J Cell Biol. 2002 May 27;157(5):865-72 [12021258.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41094-100 [12189152.001]
  • [Cites] Clin Immunol. 2003 May;107(2):129-36 [12763482.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):80-94 [12908139.001]
  • [Cites] J Virol Methods. 2004 Jan;115(1):83-92 [14656464.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):145-51 [14764043.001]
  • [Cites] Methods Mol Biol. 2004;248:161-76 [14970495.001]
  • [Cites] Protein Eng Des Sel. 2004 Jan;17(1):21-7 [14985534.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2073-83 [14978215.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):544-51 [15363805.001]
  • [Cites] Nucleic Acids Res. 1989 May 25;17(10):4000 [2734114.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6363-71 [1933899.001]
  • [Cites] J Mol Biol. 1991 Dec 5;222(3):581-97 [1748994.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3402-8 [1596900.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1883-8 [8385572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8 [8341653.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4026-34 [7689421.001]
  • [Cites] Diagn Mol Pathol. 1994 Dec;3(4):292-7 [7866641.001]
  • [Cites] Curr Opin Cell Biol. 1995 Aug;7(4):552-63 [7495576.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S33-8 [16716801.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3661-97 [16778094.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):90-8 [16736513.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Vascul Pharmacol. 2007 Jun;46(6):383-93 [17382599.001]
  • [Cites] Microbes Infect. 2007 Jul;9(8):1003-10 [17544801.001]
  • [Cites] Reprod Biol Endocrinol. 2008;6:15 [18400107.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):611-8 [10545504.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):2191-8 [10636925.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):888-95 [10878363.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6434-40 [11103810.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2323-6 [11344246.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3890-5 [11389031.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30729-36 [11406621.001]
  • [Cites] J Mol Biol. 1996 Jan 12;255(1):28-43 [8568873.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-140-S1-50 [9045311.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1405-12 [9652755.001]
  • [Cites] J Soc Gynecol Investig. 1998 Nov-Dec;5(6):334-8 [9824816.001]
  • [Cites] J Cell Biol. 1998 Dec 28;143(7):1997-2008 [9864370.001]
  • [Cites] Q J Nucl Med. 1998 Dec;42(4):225-41 [9973838.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4761-4 [10519379.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1126-36 [16151406.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1137-46 [16151407.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):336-45 [16216233.001]
  • [Cites] J Cell Sci. 2002 Mar 1;115(Pt 5):963-72 [11870215.001]
  • (PMID = 19010852.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007323; United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / R03 HD048540; United States / NCI NIH HHS / CA / R21 CA131756; United States / NCI NIH HHS / CA / P50 CA086306; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / 2-T32-AI-07323; United States / NCI NIH HHS / CA / T32 CA009120; United States / NCI NIH HHS / CA / CA009120; United States / NCI NIH HHS / CA / U54 CA119367; United States / NCI NIH HHS / CA / R21 CA131756-01A1; United States / NICHD NIH HHS / HD / R03 HD048540-02; United States / NCI NIH HHS / CA / CA86306; United States / NCI NIH HHS / CA / CA131756-01A1; United States / NICHD NIH HHS / HD / HD48540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EMP2 protein, human; 0 / Immunoglobulin Fragments; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ NIHMS290195; NLM/ PMC3109074
  •  go-up   go-down


26. Patai K, Dévényi L, Hubay M, Csömör S, Zelkó R: Phosphor/sulphur ratio: an indicator of malignant uterus change. Oncol Res; 2005;15(4):215-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphor/sulphur ratio: an indicator of malignant uterus change.
  • The purpose of the present study was to establish a correlation between gynaecological diseases (myoma, adenocarcinoma) and phosphor/sulphur (P/S) ratios of different regions of the uterus.
  • The results of the nonparametric statistical test (Wilcoxon rank-sum test) indicate that the P/S ratios were significantly higher in adenocarcinoma (0.8891 +/- 0.0757) than in myoma (0.4713 +/- 0.0306).
  • [MeSH-major] Adenocarcinoma / pathology. Leiomyoma / pathology. Phosphorus / analysis. Sulfur / analysis. Uterine Neoplasms / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822281.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphatidylcholines; 27YLU75U4W / Phosphorus; 70FD1KFU70 / Sulfur
  •  go-up   go-down


27. Jaidane M, Slama A, Bibi M: A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Nov;20(11):1393-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review.
  • We report the first case of an adenocarcinoma arising in an ectopic ureter in a woman and mimicking uterine cervical adenocarcinoma.
  • A 34-year-old woman, previously diagnosed as having bicornuate uterus, presented with post-coital bleeding.
  • After nodule biopsy, the initial diagnosis was adenocarcinoma of the uterine cervix.
  • Pelvic ultrasound and magnetic resonance imaging demonstrated an ectopic tumoral ureter draining a dysplastic pelvic kidney and inserted in the cervix of a bicornuate uterus.
  • Pathological exam demonstrated an adenocarcinoma arising in the ectopic ureter.
  • We suggest that this case could be an argument for recommending regular follow-up for women with ectopic ureter for detecting malignant transformation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Ureter. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging


28. Caquant F, Mas-Calvet M, Turbelin C, Lesoin A, Lefebvre D, Narducci F, Querleu D, Leblanc E: [Endometrial cancer by laparoscopy and vaginal approach in the obese patient]. Bull Cancer; 2006 Apr;93(4):402-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial cancer by laparoscopy and vaginal approach in the obese patient].
  • [Transliterated title] La voie d'abord chirurgicale coeliovaginale chez les patientes obèses atteintes d'un cancer de l'endomètre.
  • To prove feasibility of laparoscopic and vaginal surgical approach in obese patients with endometrial cancer, 81 patients were included retrospectively in 2 Cancer Centres : 41 obese and 40 non obese.
  • Matching 41 obese patients treated by laparoscopy with 29 obese patients with endometrial cancer treated by laparotomy, hospital stay was shorter in the laparoscopic group (3.8 [2-8] vs 7.4 days [5-10] p < 0.001) and pelvic nodes (16.3 [3-50] vs 11.5 [2-34]), operative time (149.9 [80-300] vs 167.9 minutes [60-390]) and disease-free survival (93 vs 80 %) were similar.
  • For obese patients with stage I endometrial adenocarcinoma, laparoscopic approach should be first choice because of similar operative complications and pelvic nodes, shorter hospital stay and less abdominal wall morbidity associated with lower risk to delay adjuvant radiotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Gynecologic Surgical Procedures / methods. Laparoscopy / methods. Obesity / complications

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627243.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Stewart CJ, Amanuel B, Grieu F, Carrello A, Iacopetta B: KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J Clin Pathol; 2010 Jul;63(7):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
  • BACKGROUND: Some uterine endometrioid adenocarcinomas exhibit a distinctive morphological phenotype characterised by the formation of microcystic, elongated and fragmented (MELF) glands.
  • AIMS: To investigate the molecular characteristics of endometrial tumours showing MELF, with particular reference to the frequencies of KRAS and BRAF mutations and of microsatellite instability (MSI).
  • METHODS: MSI, and KRAS and BRAF mutation status, were assessed in 33 low-grade endometrial adenocarcinomas showing MELF features and the results compared with 33 control cases exhibiting a 'conventional' pattern of myometrial invasion.
  • CONCLUSIONS: Mutations in KRAS and BRAF genes are not directly implicated in the development of a MELF pattern of invasion in endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Microsatellite Instability. Mutation. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591910.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


30. Michener CM, Peterson G, Kulp B, Webster KD, Markman M: Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol; 2005 Sep;131(9):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
  • PURPOSE: To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer.
  • METHODS: Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease.
  • With a median follow-up of 42 months, 13 patients have died of progressive cancer, while four currently have no evidence of disease at the time of last follow-up.
  • CONCLUSIONS: The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma.
  • The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-57-S15-61 [9346224.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 2):78-83 [10190786.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):397-400 [8112651.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):283-5 [9625439.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1408-14 [8021731.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1021-9 [11181665.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72 [10985896.001]
  • [Cites] Am J Clin Oncol. 1993 Dec;16(6):494-6 [8256764.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):264-7 [2013451.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):52-7 [10873410.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • (PMID = 15959825.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Kogan EA, Niziaeva NV, Demura TA, Ezhova LS, Unanian AL: [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma]. Arkh Patol; 2010 Jul-Aug;72(4):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma].
  • The purpose of the investigation was to study the morphological variants and molecular changes of the endothelial component of adenomyosis (AM) concurrent with endometrial adenocarcinoma (EAC).
  • The foci of AM, which corresponded to epithelial hyperplasia with atypia, were characterized by the oncomarker changes supporting its malignant potential: elevated Ki-67 and EGRF, reduced E-cadherin, changes in MMP-2, MMP-9, TIMP-1, and claudins-2, -3, and -5.
  • [MeSH-major] Adenocarcinoma. Endometrial Neoplasms. Endometriosis. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis


32. Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS, Southwest Oncology Group: Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol; 2005 Mar;96(3):610-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
  • OBJECTIVES: To evaluate the response rate and progression free and overall survival of patients with advanced endometrial cancer treated with paclitaxel, carboplatin and amifostine.
  • METHODS: Forty-seven eligible patients (median age: 66; range 45-82) with bidimensionally measurable advanced, recurrent, or refractory endometrial cancer were treated with carboplatin (AUC = 6), paclitaxel (175 mg/M2) and amifostine (740 mg/M2) every 4 weeks for 6 cycles or until disease progression or unacceptable toxicity.
  • The median progression-free survival (PFS) was 7 months (95% CI, 6-9 months) and a 6-month PFS rate of 64% (95% CI, 50% to 78%).
  • The regimen demonstrated significant activity in endometrial cancer, comparable to other multi-agent chemotherapy programs in terms of response rate and survival, and with a favorable toxicity profile.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721401.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03096; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA68183; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76462
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


33. Mulligan AM, Plotkin A, Rouzbahman M, Soslow RA, Gilks CB, Clarke BA: Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. Am J Surg Pathol; 2010 Aug;34(8):1132-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
  • Poorly differentiated endometrial carcinomas of specific type include the rarely reported endometrial carcinoma with a malignant giant cell component [endometrial giant cell carcinoma (GCC)].
  • The patients ranged in age from 53 to 83 years, presenting with vaginal bleeding, anemia, or a pelvic mass.
  • Four of the 5 tumors contained areas of endometrial adenocarcinoma of usual type, with a variable giant cell component.
  • The conventional cell types present included 1 case with clear cell carcinoma (30% of tumor volume), 2 with high-grade endometrioid carcinoma (50% and 70% of tumor volume, respectively) and 1 with serous histology (10% of tumor volume).
  • One was composed exclusively of giant cell carcinoma.
  • One patient in whom the tumor was exclusively of the giant cell type, developed lung metastasis 4 years after diagnosis and 1 patient is disease free after 14 years.
  • As histotype supplemented by staging information is critical in selection of treatment modalities and in prognostication in uterine malignancies, accurate classification is mandated.
  • Here, we present a series of endometrial carcinomas containing a component of GCC and discuss the spectrum of giant cell-containing uterine neoplasms.
  • At this time, however, the cumulative data on endometrial GCC are limited and the prognostic significance of the presence and the extent of a giant cell component in endometrial carcinoma remains uncertain.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Giant Cell / pathology. Endometrial Neoplasms / pathology. Giant Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588176.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 25
  •  go-up   go-down


34. García-Cao I, Duran A, Collado M, Carrascosa MJ, Martín-Caballero J, Flores JM, Diaz-Meco MT, Moscat J, Serrano M: Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep; 2005 Jun;6(6):577-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The endometrium and prostate of Par4-null mice were particularly sensitive to the development of proliferative lesions.
  • Most (80%) Par4-null females presented endometrial hyperplasia by 9 months of age, and a significant proportion (36%) developed endometrial adenocarcinomas after 1 year of age.
  • Finally, the uterus and prostate of young Par4-null mice have increased levels of the apoptosis inhibitor XIAP (X-chromosome-linked inhibitor of apoptosis), supporting the previously proposed function of Par4 as an inhibitor of the (zeta)PKC (atypical protein kinase)-NF-(kappa)B (nuclear factor-(kappa)B)-XIAP pathway.
  • These data show that Par4 has an important role in tumour suppression, with a particular relevance in the endometrium and prostate.
  • [MeSH-major] Apoptosis / physiology. Endometrial Neoplasms / metabolism. Phenotype. Prostatic Neoplasms / metabolism. Proteins / metabolism. Receptors, Thrombin / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 15;18(22):6362-9 [10562548.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):29976-83 [10514481.001]
  • [Cites] J Mol Neurosci. 1999 Aug-Oct;13(1-2):17-30 [10691289.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1012-7 [10833474.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):328-39 [11159913.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7 [11469677.001]
  • [Cites] Mol Cell. 2001 Oct;8(4):771-80 [11684013.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1801-8 [11742505.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1768-75 [11912153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4049-57 [12145205.001]
  • [Cites] EMBO J. 2002 Nov 15;21(22):6225-35 [12426394.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):31-6 [12524517.001]
  • [Cites] Exp Cell Res. 2003 Feb 1;283(1):51-66 [12565819.001]
  • [Cites] EMBO Rep. 2003 Mar;4(3):307-12 [12634851.001]
  • [Cites] Cell Cycle. 2003 Mar-Apr;2(2):71-2 [12695647.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):19995-20005 [12644474.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4689-98 [12970181.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):504-12 [14755681.001]
  • [Cites] Cell Growth Differ. 1994 Apr;5(4):457-66 [8043520.001]
  • [Cites] Cell. 1996 Sep 6;86(5):777-86 [8797824.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6945-56 [8943350.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3823-32 [9199316.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3806-11 [9731488.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1205-8 [10022126.001]
  • [Cites] Oncogene. 1999 Nov 25;18(50):7115-23 [10597313.001]
  • (PMID = 15877079.001).
  • [ISSN] 1469-221X
  • [Journal-full-title] EMBO reports
  • [ISO-abbreviation] EMBO Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / Receptors, Thrombin; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / protease-activated receptor 4; 3817-11-6 / Butylhydroxybutylnitrosamine; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC1369092
  •  go-up   go-down


35. Sameshima H, Nagai K, Ikenoue T: Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus. Gynecol Oncol; 2005 Apr;97(1):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
  • CASE: Two Japanese women had a single ectopic ureter opening in the central wall of the vagina, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
  • One had squamous cell carcinoma of the uterine cervix, and the other had adenocarcinoma of the vagina arising from the ectopic ureter meatus, which was histologically confirmed as fetal metanephric duct remnant.
  • Clinically, the ectopic vaginal ureter is important as a possible background of vaginal adenocarcinoma, and information on the ureter-like duct course is required during surgery.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Kidney / abnormalities. Ureter / abnormalities. Uterine Cervical Neoplasms / etiology. Uterus / abnormalities. Vaginal Neoplasms / etiology


36. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancer of the endometrium and ovary].
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed .
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively.
  • endometrioid carcinomas was the main pathologic type (66.7%).
  • CONCLUSION: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


37. Pan H, Sun CC, Zhou CY, Huang HF: Expression of aquaporin-1 in normal, hyperplasic, and carcinomatous endometria. Int J Gynaecol Obstet; 2008 Jun;101(3):239-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the relationship between aquaporin-1 (AQP1) and endometrial adenocarcinoma.
  • METHOD: Intratumoral microvessel density (IMD) was assessed as well as AQP1 and vascular endothelial growth factor expression in samples from 117 women, 75 with endometrioid adenocarcinoma, 17 with endometrial hyperplasia, and 25 with normal proliferative endometria.
  • In samples from endometrioid adenocarcinoma, the AQP1/IMD ratio was significantly correlated with histologic grade, surgical stage, myometrial invasion, and extrauterine metastasis.
  • CONCLUSION: AQP1 may be involved in the tumorigenesis and progression of endometrioid adenocarcinoma by promoting angiogenesis, and AQP1 level may be both a tumor indicator and a new therapeutic target.
  • [MeSH-major] Aquaporin 1 / metabolism. Carcinoma, Endometrioid / blood supply. Endometrial Neoplasms / blood supply
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Adult. Antigens, CD34 / analysis. Antigens, CD34 / immunology. Endometrial Hyperplasia / immunology. Female. Humans. Immunohistochemistry. Medical Records. Microcirculation / pathology. Middle Aged. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313673.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factors; 146410-94-8 / Aquaporin 1
  •  go-up   go-down


38. Duncan C, Powers J, Davis T, Spraker T: Abomasal and uterine adenocarcinomas with ovarian metastasis in a captive elk (Cervus elaphus nelsoni). J Vet Diagn Invest; 2007 Sep;19(5):560-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abomasal and uterine adenocarcinomas with ovarian metastasis in a captive elk (Cervus elaphus nelsoni).
  • Within the uterus there was a poorly demarcated, multilobulated mass measuring 10 cm in diameter.
  • Histologically the tumor was an adenocarcinoma.
  • A focal, 1-cm diameter adenocarcinoma was identified within the abomasum; this tumor was histologically distinct from the neoplasm found in the uterus and ovary.
  • [MeSH-major] Adenocarcinoma / veterinary. Deer. Ovarian Neoplasms / veterinary. Uterine Neoplasms / veterinary
  • [MeSH-minor] Abomasum / pathology. Animals. Female. Ovary / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823404.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of uterine malignancies.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • The concept of carcinosarcoma representing a metaplastic adenocarcinoma of the endometrium that behaves more like a carcinoma than a sarcoma is explained.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


40. Sinkevicius KW, Burdette JE, Woloszyn K, Hewitt SC, Hamilton K, Sugg SL, Temple KA, Wondisford FE, Korach KS, Woodruff TK, Greene GL: An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology; 2008 Jun;149(6):2970-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ENERKI mice had hypoplastic uterine tissues and rudimentary mammary gland ductal trees.
  • Growth factor treatments induced uterine epithelial proliferation in ovariectomized ENERKI females, directly demonstrating that ERalpha ligand-independent pathways were active.
  • In addition, the synthetic ERalpha selective agonist propyl pyrazole triol (PPT) and ER agonist diethylstilbestrol (DES) were still able to activate ligand-induced G525L ERalpha pathways in vitro.
  • PPT treatments initiated at puberty stimulated ENERKI uterine development, whereas neonatal treatments were needed to restore mammary gland ductal elongation, indicating that neonatal ligand-induced ERalpha activation may prime mammary ducts to become more responsive to estrogens in adult tissues.
  • DES did not stimulate an ENERKI uterotrophic response.
  • Because ERbeta may modulate ERalpha activation and have an antiproliferative function in the uterus, we hypothesize that ENERKI animals were particularly sensitive to DES-induced inhibition of ERalpha due to up-regulated uterine ERbeta levels.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34 [11070086.001]
  • [Cites] Development. 2000 Oct;127(19):4277-91 [10976058.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2200-4 [11356663.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1379-91 [11578956.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):36869-72 [11459850.001]
  • [Cites] Endocrinology. 2001 Nov;142(11):4751-7 [11606440.001]
  • [Cites] Genesis. 2002 Feb;32(2):99-101 [11857789.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8531-7 [11751931.001]
  • [Cites] Rev Endocr Metab Disord. 2002 Sep;3(3):193-200 [12215714.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2188-201 [12351685.001]
  • [Cites] Endocrinology. 2002 Nov;143(11):4172-7 [12399409.001]
  • [Cites] Trends Endocrinol Metab. 2002 Dec;13(10):422-7 [12431838.001]
  • [Cites] Nat Med. 2003 Jan;9(1):82-6 [12483206.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4693-702 [15231698.001]
  • [Cites] Endocrinology. 1992 Apr;130(4):1923-30 [1547720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11162-6 [8248223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1322-6 [7877975.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):358-417 [10368776.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1524-8 [10385621.001]
  • [Cites] Reproduction. 2005 Sep;130(3):283-91 [16123235.001]
  • [Cites] Diabetologia. 2006 Mar;49(3):588-97 [16463047.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26683-92 [16847062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8173-7 [17470805.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5855-65 [10579351.001]
  • [Cites] Science. 1999 Dec 17;286(5448):2328-31 [10600740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):383-7 [10618427.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):1-10 [10733896.001]
  • [Cites] Steroids. 2000 May;65(5):227-51 [10751636.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5936-41 [10823946.001]
  • [Cites] Endocrinology. 2000 Aug;141(8):2982-94 [10919287.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4688-700 [10970861.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):640-5 [11095962.001]
  • (PMID = 18339713.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD055892-03; United States / NICHD NIH HHS / HD / R01 HD044464; United States / NICHD NIH HHS / HD / K12 HD055892; United States / NICHD NIH HHS / HD / HD044464; United States / NICHD NIH HHS / HD / HD055892-03; United States / NCI NIH HHS / CA / CA89089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Ligands; 4TI98Z838E / Estradiol; 731DCA35BT / Diethylstilbestrol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ PMC2408815
  •  go-up   go-down


41. Keightley MC, Brown P, Jabbour HN, Sales KJ: F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biol; 2010 Jan 21;11:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prostaglandin (PG) F(2alpha) is a key regulator of endometrial function and exerts its biological action after coupling with its heptahelical G protein-coupled receptor (FP receptor).
  • In endometrial adenocarcinoma the FP receptor expression is elevated.
  • We have shown previously that PGF(2alpha)-FP receptor signalling in endometrial adenocarcinoma cells can upregulate several angiogenic factors including fibroblast growth factor-2 (FGF2).
  • In the present study, we investigated the paracrine effect of conditioned medium produced via PGF(2alpha)-FP receptor signalling in endometrial adenocarcinoma cells stably expressing the FP receptor (Ishikawa FPS cells), on endothelial cell function.
  • These findings have relevance for pathologies where the FP receptor is aberrantly expressed, such as endometrial adenocarcinoma, and provide in vitro evidence to suggest that targeting the FP receptor could provide an anti-angiogenic approach to reducing tumour vasculature and growth.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2008 May 8;263(1):114-21 [18243528.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 20;121(24):2599-603 [19187602.001]
  • [Cites] J Cell Sci. 2009 Jun 1;122(Pt 11):1812-22 [19435802.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):5096-103 [10671553.001]
  • [Cites] Br J Pharmacol. 2000 Jun;130(3):641-9 [10821793.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4932-8 [10987309.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):424-32 [11809691.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3087-94 [12384403.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Exp Cell Res. 2003 Nov 15;291(1):70-82 [14597409.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):157-66 [12851809.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Microvasc Res. 1977 Jul;14(1):53-65 [895546.001]
  • [Cites] Nature. 1980 Dec 11;288(5791):551-6 [6160403.001]
  • [Cites] Atherosclerosis. 1987 Jun;65(3):227-36 [3113442.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):179-83 [8931116.001]
  • [Cites] Nat Med. 1997 Aug;3(8):887-93 [9256280.001]
  • [Cites] J Biol Chem. 1997 Sep 12;272(37):23347-53 [9287347.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] J Cell Biol. 1998 Mar 9;140(5):1255-63 [9490736.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1607-16 [9626064.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):836-41 [9626350.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):614-20 [10076137.001]
  • [Cites] Mol Hum Reprod. 1999 Oct;5(10):973-82 [10508227.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6112-8 [15579767.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Vascul Pharmacol. 2006 Jun;44(6):411-6 [16651031.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jun 27;252(1-2):191-200 [16701939.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):36-44 [16905765.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):16959-68 [17401137.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Cancer Lett. 2008 Feb 8;259(2):146-55 [18006148.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3011-4 [18073529.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):2139-46 [18042549.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e4 [18241520.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9 [18061438.001]
  • [Cites] Health Stat Q. 2008 Summer;(38):33-46 [18595386.001]
  • (PMID = 20092633.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ PMC2824741
  •  go-up   go-down


42. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H: Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
  • We reported that p27 induced by medroxyprogesterone acetate (MPA) may be involved in the progestin-induced growth suppression of human endometrial adenocarcinoma cells.
  • The clinical responses of 15 patients with endometrial carcinoma treated with MPA were examined. p27 expression was evaluated by immunohistochemical staining.
  • The former was significantly higher than the latter. p27 expression could predict the effectiveness of MPA treatment for endometrial carcinoma at an early stage of the 4-month period in MPA therapy and could be a useful predicting marker for MPA.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Proliferating Cell Nuclear Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515645.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


43. Mihalcea D, Aursulesei D: [Myometrial invasion as a prognostic factor in endometrial adenocarcinoma]. Rev Med Chir Soc Med Nat Iasi; 2009 Jan-Mar;113(1):136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myometrial invasion as a prognostic factor in endometrial adenocarcinoma].
  • [Transliterated title] Invazia miometrială-factor de prognostic în adenocarcinomul endometrial.
  • Myometrial invasion is one of the most important prognostic factors in endometrial cancer.
  • MATERIAL AND METHOD: We have studied a cohort of 62 patients with endometrial cancer who underwent surgery in 4-th Gynecology Clinic of "Cuza Vodă" Hospital, Iaşi between 1997-2008.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495308.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


44. Li A, Felix JC, Minoo P, Amezcua CA, Jain JK: Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril; 2005 Jul;84(1):202-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells.
  • OBJECTIVE: To determine the mechanism by which mifepristone improves breakthrough bleeding, the effects of mifepristone on proliferation and apoptosis of Ishikawa endometrial carcinoma cells were evaluated in the presence and absence of progestin.
  • Together, these data imply that the improvement in breakthrough bleeding observed with mifepristone might be due to diminished volume of endometrial tissue similar to that seen with endometrial atrophy.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Cell Proliferation / drug effects. Endometrial Neoplasms / metabolism. Mifepristone / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009178.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R0-1 HD 43189
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


45. Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, Li C, Gardner GJ, Bonome T, Johnson WB, Smith DI, Chung TK, Birrer MJ: Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene; 2007 Mar 22;26(13):1971-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling.
  • Endometrial cancer is the third most common gynecologic malignancy and the ninth most common malignancy for females overall in Hong Kong.
  • Approximately 80% or more of these cancers are endometrioid endometrial adenocarcinomas.
  • The aim of this study was to reveal genes contributing to the development of endometrioid endometrial cancer, which may impact diagnosis, prognosis and treatment of the disease.
  • Whole-genome gene expression analysis was completed for a set of 55 microdissected sporadic endometrioid endometrial adenocarcinomas and 29 microdissected normal endometrium specimens using the Affymetrix Human U133 Plus 2.0 oligonucleotide microarray.
  • Pathway analysis was performed to reveal gene interactions involved in endometrial tumorigenesis.
  • Unsupervised hierarchical clustering displayed a distinct separation between the endometrioid adenocarcinomas and normal endometrium samples.
  • Supervised analysis identified 117 highly differentially regulated genes (>or=4.0-fold change), which distinguished the endometrial cancer specimens from normal endometrium.
  • Twelve novel genes including DKK4, ZIC1, KIF1A, SAA2, LOC16378, ALPP2, CCL20, CXCL5, BST2, OLFM1, KLRC1 and MBC45780 were deregulated in the endometrial cancer, and further validated in an independent set of 56 cancer and 29 normal samples using qRT-PCR.
  • In addition, 10 genes were differentially regulated in late-stage cancer, as compared to early-stage disease, and may be involved in tumor progression.
  • The results of this study highlight the molecular features of endometrioid endometrial cancer and provide insight into the events underlying the development and progression of endometrioid endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Gene Expression Profiling. Genome. Signal Transduction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043662.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Lee HC, Chen FF, Lo CC, Wang CJ, Lo WC, Luh SP: Metastasis of gastric carcinoma to the thyroid and lung: a case report and review of literature. J Zhejiang Univ Sci B; 2010 Jul;11(7):542-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of gastric carcinoma to the thyroid and lung: a case report and review of literature.
  • Cancer metastasis to the thyroid is extremely rare.
  • The more commonly reported primary sites for metastasis to the thyroid are the kidney, breast, lung, colon, esophagus, and uterus.
  • Wedge resection of a suspicious pulmonary nodule, detected on CT, was performed for diagnosis.
  • Poorly differentiated adenocarcinomas with the same histological profiles were noted at these three sites.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Stomach Neoplasms. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 Apr;125(4):1522-9 [15078769.001]
  • [Cites] J Zhejiang Univ Sci B. 2009 May;10(5):375-9 [19434764.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1977;(260):1-235 [269649.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):856-9 [6503368.001]
  • [Cites] Histopathology. 1987 Jun;11(6):567-80 [2442086.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):236-41 [15670202.001]
  • [Cites] Chest. 2005 Apr;127(4):1427-32 [15821225.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):93-6 [16415418.001]
  • [Cites] J Zhejiang Univ Sci B. 2006 Feb;7(2):118-28 [16421967.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] J Egypt Natl Canc Inst. 2006 Mar;18(1):67-72 [17237852.001]
  • [Cites] Int J Surg. 2008 Oct;6(5):415-7 [18947815.001]
  • [Cites] Endocr Pract. 2008 Nov;14(8):1040-6 [19095607.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • (PMID = 20593521.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2897026
  •  go-up   go-down


47. Han CP, Lee MY, Kok LF, Ruan A, Wu TS, Cheng YW, Tyan YS, Lin CY: Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol; 2009 Sep;28(5):489-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
  • Endocervical adenocarcinomas (ECAs) and endometrial adenocarcinomas (EMAs) are malignancies that affect the uterus; however, their biologic behaviors are quite different.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Endometrial Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Carcinoembryonic Antigen / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Receptors, Estrogen / biosynthesis. Tissue Array Analysis. Vimentin / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696622.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Estrogen; 0 / Vimentin
  •  go-up   go-down


48. Vorgias G, Fotiou S: The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet; 2010 Dec;282(6):659-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review.
  • BACKGROUND: Uterine carcinosarcomas are rare and highly aggressive tumours.
  • RESULTS: Carcinosarcomas have similar clinical characteristics and behaviour with grade 3 endometrioid or aggressive variants of uterine adenocarcinoma.
  • All studies have demonstrated that the FIGO stage of disease is the most important prognostic factor, followed by the depth of myometrial invasion, extra-uterine spread and positive peritoneal cytology.
  • This figure is similar to the one reported for endometrial carcinoma.
  • [MeSH-major] Carcinosarcoma / surgery. Lymph Node Excision. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721670.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


49. Chen CY, Yen MS, Yang MJ, Wu YC: Uterus didelphys with adenocarcinoma in the right cavity diagnosed by 2-dimensional sonography and magnetic resonance imaging. J Ultrasound Med; 2008 Dec;27(12):1802-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterus didelphys with adenocarcinoma in the right cavity diagnosed by 2-dimensional sonography and magnetic resonance imaging.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Magnetic Resonance Imaging / methods. Ultrasonography / methods. Uterine Neoplasms / ultrasonography. Uterus / abnormalities. Uterus / ultrasonography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023011.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


50. Miszczak-Zaborska E, Smolarek M, Dramiński M, Kubiak R, Józwiak B, Bartkowiak J: [Influence of the selected pyrimidine compounds on the activity of thymidine phosphorylase from normal and tumor endometrial cells]. Ginekol Pol; 2009 Aug;80(8):590-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of the selected pyrimidine compounds on the activity of thymidine phosphorylase from normal and tumor endometrial cells].
  • OBJECTIVES: The aim of this study was to evaluate the influence of the selected pyrimidine compounds on the activity of thymidine phosphorylase (TP) of normal and tumor endometrial cells.
  • MATERIALS AND METHODS: Influence of 28 chemical compounds on the TP activity in the cytosol of the endometrial cells was studied by the spectrophotometric method.
  • The studied group comprised postmenopausal women with endometrial cancer: adenocarcinoma endometrialis (Adeno Ca E).
  • The second group included women with normal endometrium after surgery due to non-oncologic reasons.
  • RESULTS: The most potent inhibitor of TP activity from cancer and endometrium was synthesized 5-bromo-6-acetyloaminouracil, which at the 0.2 mM concentration, by 0.2 mM concentration thymidine reduced the cytosol TP activity by about 80%.
  • From among synthesized 1-N-allyloxymethylpyrimidine derivatives 1-N-allyloxymethylthymine was the strongest inhibitor of the TP activity in endometrium, and 1-N-allyloxymethyl-4-hydrokxy-5-nitro-6-oxopyrimidine in endometrial cancer respectively.
  • The most potent activators of TP in endometrial cancer was 5-bromodeoxyuridine and 1-N-allyloxymethyl-5-nitrouracil, which increased the TP activity about 100%.
  • 5-fluorodeoxyuridine, 5-jododeoxyuridine and 2'-deoxyuridine activated the TP in statistically significant manner too, but stronger in case of endometrial cancer than in normal endometrium.
  • The synthesized 5-bromo-6-acetyloaminouracil strongly inhibited the TP activity of endometrial cells and might be useful in reducing endometrial cancer angiogenesis.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Pyrimidines / administration & dosage. Thymidine Phosphorylase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824457.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Pyrimidines; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


51. Pires MA, Seixas F, Palmeira C, Payan-Carreira R: Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma. Reprod Domest Anim; 2010 Jun;45(3):545-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma.
  • Canine endometrial carcinomas are rare, and mostly occur in geriatric bitches.
  • In this work, the uterus of a 10-year-old female Boxer evidencing an endometrial carcinoma on the body of the uterus was used to describe the histopathological features of the tumour and to study its immunophenotype.
  • In this work, a panel of immunomarkers (cytokeratins AE1/AE3 and 14, vimentin, CD10 and Ki-67) was applied to the endometrial carcinoma to establish the staining patterns indicative of the tumour agressiveness and cellular differentiation.
  • This study aims to contribute to the advancement of the knowledge in canine endometrial carcinoma immunophenotype.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / diagnosis. Endometrial Neoplasms / veterinary. Immunohistochemistry / veterinary

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144037.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


52. Abdulhathi MB, Al-Salam S, Kassis A, Ghazal-Aswad S: Unusual presentation of cervical cancer as advanced ovarian cancer. Arch Gynecol Obstet; 2007 Oct;276(4):387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of cervical cancer as advanced ovarian cancer.
  • We report a case of cervical adenocarcinoma presenting primarily as advanced ovarian cancer with the primary site totally silent.
  • Right salpingo-oophorectomy was performed with the histologic diagnosis of dermoid cyst.
  • Follow-up after 5 months showed a higher level of serum CA 125 (1,594 micro/ml) and a negative cervical smear.
  • Surprisingly, the histologic features of the specimen obtained at laparotomy were consistent with a moderately differentiated cervical adenocarcinoma with metastases to corpus uterus, ovaries, left fallopian tube, omentum and pleural cavity.
  • The final stage was stage IV cervical cancer.
  • CONCLUSION: Cervical carcinoma should be suspected in any patient presented with bilateral ovarian tumors and positive ascitic fluid cytology.
  • Negative cervical smears do not exclude the possibility of primary cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


53. Alameda F, Mejías-Luque R, Garrido M, de Bolós C: Mucin genes (MUC2, MUC4, MUC5AC, and MUC6) detection in normal and pathological endometrial tissues. Int J Gynecol Pathol; 2007 Jan;26(1):61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin genes (MUC2, MUC4, MUC5AC, and MUC6) detection in normal and pathological endometrial tissues.
  • Changes in the composition and physical properties of the mucous gel covering the endometrial surface are detected during the menstrual cycle and in pathological conditions.
  • The aim of this study is to analyze the expression patterns of the 11p15 secreted mucins, MUC2, MUC5AC, and MUC6, and the membrane-bound mucin MUC4 in proliferative and secretory normal endometrium, simple and complex hyperplasia, and endometrial adenocarcinoma.
  • A total of 98 samples, 19 of normal endometrium (11 proliferative and 8 secretor), 44 of endometrial hyperplasia (23 simple, 21 complex), and 35 of endometrial endometrioid adenocarcinomas were analyzed by immunohistochemical techniques using specific antimucin antibodies.
  • In the endometrial proliferative glandular epithelium, only MUC4 is detected (36.3% cases).
  • In simple hyperplasia, higher levels of mucins are expressed in the endometrial glands: MUC2 is detected in 8.7%, MUC4 in 43.4%, and MUC5AC and MUC6 in 13% of the samples, whereas in complex hyperplasia, decreased levels of mucin expression are found: MUC2 and MUC5AC are not detected, and MUC4 (28.5%) and MUC6 (20.4%) are positive.
  • In endometrial adenocarcinoma, MUC4 is highly detected (77.1%) and increased levels of MUC5AC and MUC6 are found (61.7% and 48.5%), whereas MUC2 is poorly detected (8.5%).
  • These findings suggest that during endometrial neoplasic transformation, increased levels of MUC4, MUC5AC, and MUC6 are detected, whereas MUC2 is only significantly detected in the secretory endometrium.
  • [MeSH-major] Endometrium / cytology. Endometrium / metabolism. Mucins / genetics. Uterine Diseases / genetics. Uterine Diseases / pathology

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197898.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


54. Barwick TD, Rockall AG, Barton DP, Sohaib SA: Imaging of endometrial adenocarcinoma. Clin Radiol; 2006 Jul;61(7):545-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrial adenocarcinoma.
  • Endometrial cancer is the most common gynaecological malignancy and the incidence rising.
  • This is important as endometrial cancer predominately occurs in postmenopausal women with co-morbidities.
  • Modern imaging provides important tools in the accurate pre-treatment assessment of endometrial cancer and may optimize treatment planning.
  • However, there is little consensus to date on imaging in the routine preoperative assessment of endometrial carcinoma and practice varies amongst many gynaecologists.
  • Transvaginal ultrasound is often the initial imaging examination for women with uterine bleeding.
  • However, once the diagnosis of endometrial cancer has been made, contrast-enhanced magnetic resonance imaging (MRI) provides the best assessment of the disease.
  • The results of contrast-enhanced MRI may identify patients who need more aggressive therapy and referral to a cancer centre.
  • In this article we review the role of imaging in the diagnosis and staging/preoperative assessment of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Neoplasm Invasiveness. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784939.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 87
  •  go-up   go-down


55. Rathi V, Hyde S, Newman M: Well-differentiated papillary mesothelioma in association with endometrial carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary mesothelioma in association with endometrial carcinoma: a case report.
  • We present a rare case of WDPM in association with high-grade endometrial carcinoma.
  • To our knowledge, there are only two previously reported cases in the English literature of WDPM in association with endometrial carcinoma.
  • CASE: A 62-year-old woman underwent pelvic surgery for a high-grade endometrial adenocarcinoma.
  • Cytologic examination of peritoneal washings revealed cohesive clusters of reactive-appearing mesothelial cells, some with papillary morphology, and no evidence of adenocarcinoma.
  • The peritoneal biopsies showed no metastatic carcinoma.
  • The endometrial tumor was an endometrioid adenocarcinoma.
  • CONCLUSION: The cytologic diagnosis of WDPM may be difficult because it is an uncommon entity and there are overlapping features with other neoplastic and nonneoplastic lesions of the female genital tract and peritoneum.
  • [MeSH-major] Carcinoma, Papillary / complications. Carcinoma, Papillary / pathology. Cell Differentiation. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Mesothelioma / complications. Mesothelioma / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053542.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Yoshida M, Matsuda H, Furuya K: Successful treatment of gastric cancer in pregnancy. Taiwan J Obstet Gynecol; 2009 Sep;48(3):282-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of gastric cancer in pregnancy.
  • OBJECTIVE: Gastric cancer during pregnancy is rare, and even in Japan where a high rate of gastric cancers are reported, only 0.016% of pregnant women suffer from this disease.
  • Generally, the cancer is already advanced at the time of detection and the prognosis for the woman is usually extremely poor.
  • CASE REPORT: We report a case of gastric cancer in a 32-year-old pregnant woman, gravida 6, para 4.
  • The mother and the neonate had good prognoses after early diagnosis, cesarean delivery and surgery.
  • CONCLUSION: Diagnosis of gastric cancer in pregnant women is often delayed even when they are symptomatic, because the symptoms are taken to be symptoms of hyperemesis or expansion of the uterus.
  • This case highlights the importance of early detection of gastric cancer for a positive prognosis, considering the rapidity with which gastric cancer advances in pregnancy.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Signet Ring Cell / surgery. Pregnancy Complications, Neoplastic / surgery. Pregnancy Outcome. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797021.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Ilha MR, Newman SJ, van Amstel S, Fecteau KA, Rohrbach BW: Uterine lesions in 32 female miniature pet pigs. Vet Pathol; 2010 Nov;47(6):1071-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine lesions in 32 female miniature pet pigs.
  • Uterine lesions were present in all except 8 pigs.
  • The 24 remaining pigs had diffuse cystic endometrial hyperplasia, of which 14 had smooth muscle tumors, including leiomyomas and leiomyosarcomas, in the uterus or broad ligament.
  • Nodular endometrial lesions-including adenocarcinomas, adenomas, and/or adenomyosis-were present in 10 pigs, 3 of which had concurrent smooth muscle tumors.
  • In uterine sections with cystic endometrial hyperplasia, adenomyosis, or adenomas, approximately 70% of epithelial nuclei expressed estrogen receptor and progesterone receptor immunohistochemically; in adenocarcinomas, expression was 20%.
  • Aging was associated with the development of uterine lesions in miniature pet pigs.
  • [MeSH-major] Swine Diseases / pathology. Swine, Miniature / anatomy & histology. Uterine Diseases / veterinary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Adenoma / pathology. Adenoma / veterinary. Animals. Broad Ligament / pathology. Endometrial Hyperplasia / pathology. Endometrial Hyperplasia / veterinary. Endometrium / pathology. Estrogens / blood. Female. Leiomyoma / pathology. Leiomyoma / veterinary. Leiomyosarcoma / pathology. Leiomyosarcoma / veterinary. Progesterone / blood. Pyometra / pathology. Pyometra / veterinary. Swine. Uterine Neoplasms / pathology. Uterine Neoplasms / veterinary. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20817893.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


58. Nakayama H, Sano T, Motegi A, Oyama T, Nakajima T: Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int; 2005 Nov;55(11):707-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma.
  • Lack of its expression due to hypermethylation of CpG islands has been reported in some carcinomas.
  • Here, we investigated the expression of 14-3-3 sigma, hormone receptors, Efp and p53 in 86 cases of endometrial adenocarcinoma and 46 cases of normal or non-neoplastic endometria by means of immunohistochemistry and methylation-specific polymerase chain reaction.
  • In normal endometrium, 14-3-3 sigma was overexpressed in the mid- to late-secretory phase due to hypomethylation.
  • In endometrial adenocarcinoma, 14-3-3 sigma expression was low in low grade endometrioid adenocarcinoma due to hypermethylation, and increased significantly with increasing histological grade due to hypomethylation.
  • These results suggest that 14-3-3 sigma was one of the menstrual cycle-related proteins regulated by epigenetic methylation, and its expression was influenced by epigenetic methylation or hormone receptors in progression of endometrial adenocarcinoma, and therefore was more than just a cell-cycle regulator.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Endometrial Neoplasms / metabolism. Estrogen Receptor alpha / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Adolescent. Adult. Cell Cycle. Disease Progression. Endometrium / immunology. Endometrium / metabolism. Exoribonucleases. Female. Genes, Tumor Suppressor / physiology. Humans. Immunohistochemistry. Lymphatic Metastasis. Menstrual Cycle. Methylation. Middle Aged. Nuclear Proteins / immunology. Nuclear Proteins / metabolism. Nuclear Proteins / physiology. Polymerase Chain Reaction. Tumor Suppressor Proteins. Ubiquitin-Protein Ligases

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271083.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 6.3.2.19 / TRIM25 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


59. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol; 2007 Dec;20(12):1263-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
  • Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is a newly identified oncofetal mRNA-binding protein that is involved in embryogenesis and carcinogenesis of some malignant neoplasms.
  • To investigate the diagnostic and clinicopathologic significance of this protein in endometrial carcinomas, we evaluated immunohistochemical expression of IMP3 in the two most common forms of endometrial malignancies, endometrioid adenocarcinoma and serous carcinoma.
  • We selected 167 endometrial adenocarcinoma cases including 122 cases of endometrioid adenocarcinoma and 45 cases of serous carcinoma.
  • Twenty samples of benign endometrium obtained from 20 patients with nonmalignant uterine lesions were used as controls.
  • Positive immunohistochemical stain for IMP3 was identified in all serous carcinoma cases, among which, 39 (86%) and 3 (7%) cases showed IMP3 immunoreactivity in >50%, and 21-50, or 6-20% of tumor cells, respectively.
  • Immunohistochemical reaction intensity for IMP3 was identified to be strong in 38 (84%) and intermediate in 7 (16%) cases of serous carcinoma.
  • Fifty-four (44%) cases of endometrioid adenocarcinoma were negative for IMP3.
  • Thirty (25%), 20 (16%), 10 (8%), and 8 (7%) cases of endometrioid adenocarcinoma demonstrated positive immunoreactivity for IMP3 in 1-5, 6-20, 21-50, and >50% of the tumor cells.
  • Strong IMP3-staining intensity was noted in 34 (28%), intermediate in 26 (21%), and weak in 8 (7%) cases of endometrioid adenocarcinoma.
  • To compare p53 with IMP3 expressions, we found that 35 (78%) of the serous carcinoma cases showed strong p53 immunohistochemical activity in >50% of the tumor cell nuclei.
  • In contrast, 11 of 112 (10%) endometrioid adenocarcinoma cases demonstrated strong p53 positivity in >50% of the tumor cell nuclei.
  • In conclusion, our findings demonstrate significant expression of IMP3 in serous carcinoma as compared to endometrioid adenocarcinoma (P<0.0001).
  • Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma.
  • In addition, expression of IMP3 in endometrioid adenocarcinoma correlates with higher nuclear and architecture grades of the tumor (P=0.0000 and P=0.0002, respectively).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885673.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / oncofetal antigens
  •  go-up   go-down


60. Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW: Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J Biol Chem; 2006 Jun 23;281(25):17011-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Separating the co-receptor actions of betaglycan toward inhibin and TGFbeta will allow the clarification of the role of betaglycan in disease states such as renal cell carcinoma and endometrial adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Valine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621788.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-13527
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteoglycans; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 145170-29-2 / betaglycan; 57285-09-3 / Inhibins; HG18B9YRS7 / Valine
  •  go-up   go-down


61. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ: Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol; 2009 Oct;115(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
  • OBJECTIVE: To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation.
  • METHODS: The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed.
  • Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure.
  • Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632709.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of recurrent disease or in women with residual disease after surgery, a platinum-based regimen or enrollment in a clinical trial is recommended.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


63. Balasenthil S, Broaddus RR, Kumar R: Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol; 2006 Jun;37(6):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas.
  • Endometrial carcinoma is one of the most common malignancies of the female genital tract.
  • Metastasis-associated protein 1 (MTA1) is a component of the Mi-2/nucleosome remodeling and deacetylating complex and acts as a potent corepressor of estrogen receptor in breast cancer cells.
  • MTA1 expression has been demonstrated in various cancers but has never been explored in endometrial carcinoma.
  • We investigated the expression profile of MTA1 in different stages of benign endometrium as well as in endometrial endometrioid adenocarcinoma using immunohistochemistry and Western blotting.
  • Immunohistochemical staining performed on tumor microarray containing 70 endometrial endometrioid adenocarcinomas of various grades showed increased expression of MTA1 in 53 (75.7%) tumors.
  • Our results suggest a potential role of MTA1 in endometrial carcinomas.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Endometrium / metabolism. Gene Expression. Histone Deacetylases / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733204.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


64. Hebbar V, Damera G, Sachdev GP: Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer; 2005 Sep 27;5:124
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MUC genes in endometrial and cervical tissues and tumors.
  • The objective of this study was to investigate the expression of human MUC genes (MUC1, MUC2, MUC5B, MUC5AC and MUC8) in human endometrium and cervix, and to compare and quantitate the expression of MUC genes in normal and cancerous tissues.
  • RESULTS: Of the five-mucin genes studied, MUC1, MUC5B and MUC8 showed high expression levels in the normal and cancerous endometrial and cervical tissues, MUC2 and MUC5AC showed considerably lower expression.
  • Statistically, higher levels of MUC1, MUC5B and MUC8 were observed in endometrial adenocarcinomas compared to normal tissues.
  • CONCLUSION: Endometrial tumors showed increased expression of MUC1, MUC5B and MUC8 over normal tissues.
  • Low to neglible levels of MUC2 and MUC5AC were observed in all studied endometrial and cervical tissues.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):118-26 [8604237.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):856-61 [11093805.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15386-96 [11278696.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] J Korean Med Sci. 2002 Feb;17(1):29-33 [11850585.001]
  • [Cites] J Pathol. 2002 Aug;197(5):632-7 [12210083.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Jpn J Clin Oncol. 2002 Dec;32(12):525-9 [12578901.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Mar;28(3):267-70 [12594051.001]
  • [Cites] Am J Reprod Immunol. 1996 Mar;35(3):261-6 [8962658.001]
  • [Cites] Fertil Steril. 1996 Aug;66(2):316-26 [8690123.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Mar;16(3):232-41 [9070607.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] J Surg Oncol. 2003 Aug;83(4):253-60 [12884239.001]
  • [Cites] Hum Reprod. 1988 Oct;3(7):826-34 [3182973.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Hum Reprod. 1989 Apr;4(3):236-42 [2469695.001]
  • [Cites] Biochem J. 1990 Mar 15;266(3):757-63 [1691631.001]
  • [Cites] Eur J Biochem. 1990 May 20;189(3):475-86 [2112460.001]
  • [Cites] Tumour Biol. 1990;11(5):274-86 [1697426.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] J Reprod Fertil. 1991 Jul;92(2):525-41 [1886107.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Am J Physiol. 1992 Oct;263(4 Pt 1):L413-29 [1415719.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • [Cites] Fertil Steril. 1993 Dec;60(6):1011-9 [7694876.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] Eur J Biochem. 1994 Sep 1;224(2):787-95 [7925397.001]
  • [Cites] Crit Rev Oncol Hematol. 1994 Dec;17(3):153-80 [7865137.001]
  • [Cites] Hum Reprod. 1995 Jan;10(1):98-102 [7745080.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3639-47 [7628404.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):58-64 [9858486.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Ann Thorac Surg. 1999 Mar;67(3):810-4 [10215233.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):121-7 [10424790.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):466-9 [10502721.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2240-5 [10521973.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):398-403 [15816444.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):473-83 [10763814.001]
  • [Cites] Clin Biochem. 2000 Apr;33(3):167-73 [10913513.001]
  • [Cites] Tumour Biol. 1996;17(3):176-92 [8638091.001]
  • (PMID = 16188033.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL34012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC5B protein, human; 0 / MUC8 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-5B; 0 / Mucins; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC1249559
  •  go-up   go-down


65. Bollmann J, Ortmann O, Treeck O: Expression of differentiation-associated gene icb-1 is estrogen-responsive in ovarian and breast cancer cell lines. J Steroid Biochem Mol Biol; 2008 Mar;109(1-2):16-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of differentiation-associated gene icb-1 is estrogen-responsive in ovarian and breast cancer cell lines.
  • icb-1 (C1orf38) is a human gene initially described by our group to be upregulated during in vitro differentiation processes of endometrial adenocarcinoma and leukemia cells triggered by different stimuli.
  • Given that estrogens are known to regulate cellular differentiation processes of hormone-dependent tissues, we studied whether expression of icb-1 would be regulated by 17-beta (beta) estradiol in breast and ovarian cancer cells.
  • As examined by means of real time PCR, treatment with 17-beta estradiol for at least 24h resulted in a significant increase of icb-1 transcript levels in ERalpha-positive MCF-7 breast cancer and OVCAR-3 ovarian cancer cells, but not in ERalpha-negative SK-BR-3 and SK-OV-3 cells.
  • Upregulation of icb-1 transcript levels was also observed after treatment with specific ERalpha-agonist PPT and was inhibited by co-treatment with pure antiestrogen ICI 182,780 in MCF-7 and OVCAR-3 ovarian cancer cells.
  • The results of this study demonstrate that transcript levels of differentiation-associated gene icb-1 are estrogen-responsive in breast and ovarian cancer cells in an ERalpha-dependent manner.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206364.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C1orf38 protein, human; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 4TI98Z838E / Estradiol
  •  go-up   go-down


66. Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep; 2009 Nov;22(5):1149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD24 overexpression in cancer development and progression: a meta-analysis.
  • To shed light on this controversy, we performed a meta-analysis of the relationship between CD24 expression and prognostic parameters in different carcinomas.
  • The frequency of CD24 expression by immunohistochemistry was 68% in all the carcinomas of the breast, female genital tract, gastrointestinal tract, biliary tract and pancreas, urinary system, prostate and skin.
  • Overall, CD24 was more frequently overexpressed in their carcinomas than their benign lesions (OR=4.21; 95% CI, 1.826-9.731; P=0.001) and was significantly associated with lymph node metastasis (OR=2.41; CI, 1.013-5.720; P=0.047), advanced clinical stages (OR=1.59; 95% CI, 1.244-2.032; P<0.001) and shortened overall survival (HR=2.13; 95% CI, 1.656-2.730; P<0.001).
  • CD24 expression was highly associated with lymph node metastases in breast cancer (OR=3.55; 95% CI, 1.664-7.554; P=0.001), advanced clinical stages (OR=2.22; 95% CI, 1.442-3.418; P<0.001) and lymphovascular invasions (OR=2.78; 95% CI, 1.522-5.068; P=0.001) in urothelial carcinomas and with higher grades in endometrial adenocarcinomas (OR=3.88; 95% CI, 1.548-9.715; P=0.004).
  • CD24 was more frequently and strongly expressed in breast (OR=35.80; 95% CI, 8.907-143.921; P<0.001) and ovarian carcinomas (OR=35.92; CI, 7.156-180.311; P<0.001), than in their benign counterparts.
  • In particular, CD24 may promote cancer development and progression in the breast, ovary and urinary bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787233.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Wang XY, Pan ZM, Chen XD, Lü WG, Xie X: Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma. Chin Med J (Engl); 2009 Aug 20;122(16):1843-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma.
  • BACKGROUND: Preoperative tumor grading becomes one of the most important predictors for lymphadenectomy at primary surgery for clinical stage I endometriod adenocarcinoma.
  • This study aimed to evaluate the accuracy of tumor grade by preoperative curettage so as to achieve a better stratified management for clinical stage I endometriod adenocarcinoma.
  • METHODS: Clinical data of totally 687 patients with clinical stage I endometriod adenocarcinoma who underwent preoperative curettage and primary surgery were retrospectively collected.
  • Compared with final hysterectomy specimens, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of tumor grade by preoperative curettage were calculated and their associations with clinicopathologic parameters, including age, status of menopause, position of uterus, location and size of lesion, histological grade, depth of myometrial invasion, cervical invasion, extrauterine spread, peritoneal cytology, metastasis to retroperitoneal lymph node, serum CA125 level, and hormone receptor status, were analyzed.
  • Complete surgical staging seems to be necessary for clinical stage I endometriod adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Curettage / methods. Endometrial Neoplasms / diagnosis. Neoplasm Staging / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781357.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Hsu MI, Chou SY, Lin SE, Liang SJ, Chiu HC, Hsu CS: Very early stage adenocarcinoma arising from adenomyosis in the uterus. Taiwan J Obstet Gynecol; 2006 Dec;45(4):346-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very early stage adenocarcinoma arising from adenomyosis in the uterus.
  • OBJECTIVE: Malignant transformations of adenomyosis in premenopausal women with normal endometrium are extremely rare.
  • We report a case of adenocarcinoma arising from an adenomyotic focus in the uterus, which was found unexpectedly in a woman undergoing myomectomy for adenomyosis.
  • She was admitted and underwent myomectomy under the initial diagnosis of uterine leiomyoma.
  • Microscopic studies revealed endometrioid adenocarcinoma, which was a malignant transformation of a focus of adenomyosis in the surgical specimen.
  • The endometrium had normal thickness with mild proliferative activity throughout the cavity.
  • There was no atrophic or hyperplastic change in the whole endometrium.
  • The adenocarcinoma was present exclusively in the myometrium, and a transition between the carcinoma and the adenomyotic glands was observed.
  • CONCLUSION: This case report presents evidence that adenocarcinoma may a rise de novo from an adenomyotic lesion in the uterus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Endometriosis / surgery. Uterine Diseases / surgery
  • [MeSH-minor] Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Middle Aged. Myometrium / pathology. Premenopause

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175497.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Wang XW, Ni DF: [Investigation of the characters of cervical lymph node metastases of primary malignant tumor beyond head and neck]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Jun;42(6):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of the characters of cervical lymph node metastases of primary malignant tumor beyond head and neck].
  • METHODS: Among 466 cases of malignant tumor with cervical lymph node metastases treated in Peking Union Medical College Hospital from January 1989 to June 2004, 77 cases of tumor which sites primarily beyond head and neck were studied.
  • RESULTS: The primary sites of these 77 cases of malignant tumor consisted of lung, stomach, esophagus, galactophore, colon, mediastinum, ovary, uterus, pancreas, liver, mesentery, adrenal gland and rectum.
  • The proportion of the metastases of malignant tumor from primary site beyond head and neck in each region was 2.1% in LEVEL I, 3.7% in LEVEL III, 14.3% in LEVEL IV, 70.8% in LEVEL V.
  • Among the cervical lymph node metastases of primary tumor beyond head and neck, 51.9% were low-grade adenocarcinoma, 15.6% were medial-grade adenocarcinoma, 11.7% were low-grade squamous cell carcinoma, 10.4% were medial-grade squamous carcinoma.
  • CONCLUSIONS: The cervical lymph node metastases of malignant tumor might be seen from many organs beyond head and neck.
  • The histological type of the primary tumors were frequently low-medial grade carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702413.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Ko ML, Jeng CJ, Chen SC, Tzeng CR: Sonographic appearance of fallopian tube carcinoma. J Clin Ultrasound; 2005 Sep;33(7):372-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic appearance of fallopian tube carcinoma.
  • Fallopian tube carcinoma is the least common of gynecological malignancies.
  • Transvaginal sonography revealed a cystic lesion of the fallopian tube with papillary projections, distinct from the ovary and uterus.
  • [MeSH-major] Adenocarcinoma, Papillary / ultrasonography. Fallopian Tube Neoplasms / ultrasonography. Fallopian Tubes / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc
  • (PMID = 16196007.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


71. Tamura T, Jobo T, Watanabe J, Kanai T, Kuramoto H: Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):821-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium.
  • This study aimed to clarify neuroendocrine features (NEF) in poorly differentiated (G3) endometrioid adenocarcinoma of the endometrium and to evaluate its prognostic significance.
  • Forty cases with G3 carcinoma were investigated for NEF immunohistochemically.
  • A patient with diffusely positive staining for both chromogranin A and synaptophysin was diagnosed with neuroendocrine carcinoma.
  • NEF was detected immunohistochemically in approximately 63% of the G3 carcinomas, and these patients had a poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Endometrial Neoplasms / pathology. Neurosecretory Systems / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681768.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


72. Giralt J, Regadera JP, Verges R, Romero J, de la Fuente I, Biete A, Villoria J, Cobo JM, Guarner F: Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys; 2008 Jul 15;71(4):1213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial.
  • PURPOSE: To determine whether a probiotic drink containing Lactobacillus casei DN-114 001 reduces the incidence of radiation-induced diarrhea in patients with gynecologic cancer.
  • METHODS AND MATERIALS: Patients who were undergoing pelvic radiotherapy (45-50 Gy, conventional fractionation) for either cervical carcinoma (radiotherapy and weekly cisplatin) or endometrial adenocarcinoma (postoperative radiotherapy) were randomly assigned to a probiotic drink or placebo, in a double-blind fashion.

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243569.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents
  •  go-up   go-down


73. Treeck O, Kindzorra I, Pauser K, Treeck L, Ortmann O: Expression of icb-1 gene is interferon-gamma inducible in breast and ovarian cancer cell lines and affects the IFN gamma-response of SK-OV-3 ovarian cancer cells. Cytokine; 2005 Nov 3;32(3-4):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of icb-1 gene is interferon-gamma inducible in breast and ovarian cancer cell lines and affects the IFN gamma-response of SK-OV-3 ovarian cancer cells.
  • Icb-1 (C1orf38) is a human gene initially described to be involved in in vitro differentiation processes of endometrial adenocarcinoma and leukemia cells.
  • In this study, we examined the effect of interferon-gamma on icb-1alpha and beta mRNA levels in human cell lines derived from breast cancer and gynecological malignancies.
  • Furthermore, we intended to approach icb-1 gene function by means of RNA interference (RNAi) to analyze the effect of an icb-1 knockdown on human cancer cells in vitro.
  • Three breast cancer cell lines (MCF-7, SK-BR-3, MDA-MB-231), three ovarian cancer cell lines (SK-OV-3, OVCAR-3 and BG-1) and the endometrial adenocarcinoma cell line HEC-1-A were treated with interferon gamma and the transcript levels of icb-1 isoforms alpha and beta were assessed by means of semiquantitative real-time RT-PCR.
  • Our data demonstrates an interferon-gamma triggered upregulation of icb-1alpha mRNA levels in all breast cancer cell lines and an increase of icb-1beta mRNA in MDA-MB-231 cells.
  • The strongest (about 10-fold) increase of icb-1alpha and beta mRNA after treatment with interferon-gamma was observed in ovarian cancer cell line SK-OV-3.
  • In conclusion, we report identification of the novel interferon-gamma inducible gene icb-1 which is able to affect the response of ovarian cancer cells to this cytokine.
  • [MeSH-minor] Cell Line, Tumor. Endometrial Neoplasms / metabolism. Female. Humans. Intracellular Signaling Peptides and Proteins. Protein Isoforms / biosynthesis. Protein Isoforms / genetics. Protein Isoforms / physiology. RNA Interference. RNA, Messenger / biosynthesis. Up-Regulation / genetics


74. Sobel G, Németh J, Kiss A, Lotz G, Szabó I, Udvarhelyi N, Schaff Z, Páska C: Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol; 2006 Nov;103(2):591-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
  • OBJECTIVE: The expression of claudins, the main tight junction proteins involved in cell adhesion and carcinogenesis, was studied in endometrioid (type I) and seropapillary (type II) endometrial adenocarcinoma.
  • The characteristics and possible diagnostic potential of claudin expression pattern were investigated in the two cancer types having different prognosis.
  • METHODS: Protein and mRNA expression of claudins was evaluated in 17 endometrioid carcinomas and 15 seropapillary adenocarcinomas by immunohistochemistry and real-time PCR in comparison with 38 cases of hyperplasia, normal proliferative and secretory endometrium samples.
  • RESULTS: In endometrioid carcinoma and hyperplasia low claudin 1 and high claudin 2 protein contents, whereas in seropapillary adenocarcinoma high claudin 1 and low claudin 2 levels were detected.
  • Intense protein expression was noted for claudins 3, 4, 5, and 7, without significantly different patterns in carcinoma, hyperplasia, secretory, and proliferative endometrium.
  • CONCLUSION: The two types of endometrial adenocarcinomas were well distinguished by claudins 1 and 2 by immunohistochemistry, claudins 3, 4, and 7, however, did not prove useful in distinguishing the two entities.
  • The similar claudin pattern seen in hyperplasia and endometrioid carcinoma and the differences regarding seropapillary adenocarcinoma support the dualistic model of endometrial carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Membrane Proteins / biosynthesis
  • [MeSH-minor] Claudin-1. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797678.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


75. Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG: p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol; 2010 Mar;116(3):533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
  • OBJECTIVE: The aim of this study was to evaluate the prognostic impact of p53 alteration in human uterine endometrial adenocarcinoma.
  • METHODS: One hundred and thirty-one patients with primary endometrial adenocarcinoma were included in the study.
  • Statistically significant correlations were seen between p53 alteration and non-endometrioid histology type, high grade tumors, and the absence of progesterone receptor.
  • Multivariate analyses showed that both p53 alteration and FIGO stage at diagnosis were adverse prognostic factors.
  • CONCLUSION: p53 alteration defines a subset of endometrial adenocarcinoma with highly aggressive behavior and predicts lower survival in patients with endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006376.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Chatzipantelis P, Karvouni E, Fragoulidis GP, Voros D, Pafiti A: Clinicopathologic features of two rare cases of mesenchymal metastatic tumors in the pancreas: review of the literature. Pancreas; 2006 Oct;33(3):301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second case concerns a 66-year-old woman with a history of uterus leiomyosarcoma (10 years ago) with left axillary and right femoral metastases.
  • CONCLUSIONS: The cases of metastatic uterus leiomyosarcoma and the metastatic intracranial chondrosarcoma are, to our knowledge, the first to be described.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Chondrosarcoma / pathology. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17003653.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Patel S, Portelance L, Gilbert L, Tan L, Stanimir G, Duclos M, Souhami L: Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1438-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer.
  • PURPOSE: To retrospectively assess prognostic factors and patterns of recurrence in patients with pathologic Stage III endometrial cancer.
  • METHODS AND MATERIALS: Between 1989 and 2003, 107 patients with pathologic International Federation of Gynecology and Obstetrics Stage III endometrial adenocarcinoma confined to the pelvis were treated at our institution.
  • Age, histology, grade, uterine serosal invasion, adnexal involvement, number of extrauterine sites, and treatment with adjuvant RT predicted for improved survival in univariate analysis.
  • Multivariate analysis revealed that grade, uterine serosal invasion, and treatment with adjuvant RT were independent predictors of survival.
  • CONCLUSIONS: Multiple prognostic factors predicting for the outcome of pathologic Stage III endometrial cancer patients were identified in this analysis.
  • [MeSH-major] Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418961.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Wong YF, Cheung TH, Lo KW, Yim SF, Chan LK, Buhard O, Duval A, Chung TK, Hamelin R: Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis; 2006 May;27(5):951-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers.
  • The aim of this study was to find the optimal set of microsatellite markers for diagnosis of the microsatellite instability (MSI) phenotype in endometrial cancers.
  • We compared the sensitivity, specificity and ease of use of a reference panel of five markers originally recommended by the National Cancer Institute (NCI) for colorectal cancer and a panel of five quasi-monomorphic mononucleotide repeat markers (pentaplex PCR system).
  • We used these panels for establishing the MSI status of a series of 80 sporadic endometrial adenocarcinomas by comparing the allelic profiles of the markers between tumor and matching germline DNA.
  • Both panels detected the same subset of 21 out of 80 (26%) endometrial MSI carcinomas.
  • As demonstrated previously in gastric and colon MSI cases, the pentaplex PCR reaction using mononucleotide repeats is thus an easier and more sensitive method than the NCI panel, for the screening of MSI status in endometrial tumors.
  • [MeSH-minor] DNA / chemistry. Dinucleotide Repeats / genetics. Endometrial Neoplasms / genetics. Endometrial Neoplasms / metabolism. Female. Genomic Instability. Humans. National Institutes of Health (U.S.). Phenotype. Polymerase Chain Reaction. United States

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490738.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-49-2 / DNA
  •  go-up   go-down


79. Florio P, De Falco G, Leucci E, Torricelli M, Torres PB, Toti P, Dell'Anna A, Tiso E, Santopietro R, Leoncini L, Petraglia F: Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol; 2006 Jul;190(1):99-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urocortin expression is downregulated in human endometrial carcinoma.
  • The human endometrium expresses both UCN and CRF, and CRF/UCN receptors type-1 (CRF-R1) and -2 (CRF-R2).
  • CRF-R1 activation inhibits cell growth and proliferation of a tumor cell line derived from the human endometrium, and the UCN signaling pathway has been implicated in tumorigenesis of several tissues.
  • Therefore, we investigated whether UCN mRNA and peptide are expressed by human endometrial adenocarcinoma, and whether their expression changes compared to controls.
  • Samples of well (grade 1; n = 6 endometrioid adenocarcinoma, of whom n = 1 with squamous differentiation, and n = 1 clear-cell carcinoma) and poorly differentiated (grade 3; n = 3 endometrioid adenocarcinoma) endometrial adenocarcinoma were collected from nine women (age range 61-79 years) enrolled at the time of diagnosis.
  • Healthy endometrium was collected from postmenopausal women (controls; n = 13; age range 64-78 years), who underwent hysterectomy for uterine prolapse.
  • UCN mRNA expression was significantly reduced (P < 0.0001) in endometrial adenocarcinoma than in healthy controls.
  • UCN mRNA and peptide expressions are decreased in endometrial adenocarcinoma.
  • These data and the evidence that endometrial cancer expresses UCN receptors and UCN is involved in tumorigenesis of several tissues together suggest a role for UCN in endometrial tumoral cell growth and proliferation.
  • [MeSH-major] Adenocarcinoma / metabolism. Corticotropin-Releasing Hormone / metabolism. Down-Regulation. Endometrial Neoplasms / metabolism
  • [MeSH-minor] Aged. Case-Control Studies. Endometrium / chemistry. Endometrium / metabolism. Female. Humans. Immunohistochemistry / methods. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Urocortins

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837614.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Urocortins; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


80. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


81. Shimizudani N, Senba S, Komiyama M, Hatao H, Ito M, Kioi K, Sudo A, Kishi K, Yagyu H, Oh-ishi S, Nakamura H, Matsuoka T: [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2005 Apr;43(4):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma].
  • No malignant cells were found in bilateral pleural effusions.
  • Computed tomography (CT) of the abdomen showed a huge mass of the right ovary with a small amount of ascites, suggesting a diagnosis of Meigs syndrome.
  • The ovarian mass and the neighboring organs, including the uterus and the greater omentum, were surgically removed, and then both the bilateral pleural effusion and ascites disappeared after the surgery.
  • The histopathological examination revealed that the mass was clear cell adenocarcinoma of the ovary (stage IIc), indicating that the disease was pseudo-Meigs Syndrome.
  • This is the second report of pseudo-Meigs Syndrome caused by clear cell adenocarcinoma of the ovary in Japan.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Adenocarcinoma, Clear Cell / surgery. Meigs Syndrome / etiology. Ovarian Neoplasms / complications. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME: Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol; 2005 Jun;97(3):755-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.
  • OBJECTIVE: To evaluate toxicity, survival, and recurrence-free interval in women with loco-regionally advanced endometrial carcinoma treated with postoperative whole abdominal radiation therapy.
  • RESULTS: Of 180 evaluable patients entered on the study with surgically staged III and IV endometrial carcinoma maximally debulked to less than 2 cm, 77 had typical endometrial adenocarcinoma and 103 had high-risk histology, either papillary serous or clear cell carcinoma.
  • Patients with typical endometrial adenocarcinoma were significantly younger and had significantly fewer poorly differentiated cancers.
  • Proportionally, there were twice as many non-Whites with high-risk histologies as non-Whites with typical endometrial adenocarcinoma.
  • Forty-five percent of patients with typical endometrial adenocarcinomas had positive pelvic nodes compared to 51% of those with high-risk histologies.
  • The recurrence-free survival rates were 29% and 27% (at 3 years) for the typical endometrial adenocarcinoma and high-risk histologies, respectively.
  • CONCLUSION: Whole abdominal irradiation in maximally resected advanced endometrial carcinoma has tolerable toxicity, and it is suggested that the outcome may be improved by this adjunctive treatment in patients with completely resected disease.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Cystadenocarcinoma, Papillary / radiotherapy. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913742.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


83. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol; 2005 Jun;97(3):924-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.
  • BACKGROUND: Intrauterine progesterone therapy potentially provides a simple alternative treatment for women with Stage I Grade I endometrial cancers who are at high risk for surgery.
  • The case histories of four women with early endometrial cancer primarily treated with levonorgestrel intrauterine system (Mirena) are reported and the literature reviewed.
  • CASES: Four women had Stage I grade 1 endometrial adenocarcinoma with positive progesterone receptor.
  • One of three women who did not respond to treatment subsequently had a vaginal hysterectomy, which showed endometrial cancer with superficial myometrial invasion.
  • CONCLUSION: This report raises doubts about the effectiveness of intrauterine progesterone therapy as a definitive alternative for the treatment of early endometrial cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Levonorgestrel / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Routes. Female. Humans. Middle Aged. Uterus

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943993.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 13
  •  go-up   go-down


84. Takacs P, De Santis T, Nicholas MC, Verma U, Strassberg R, Duthely L: Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease. J Ultrasound Med; 2005 Nov;24(11):1477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease.
  • OBJECTIVE: The purpose of this study was to assess postmenopausal women with endometrial fluid collection and the risk of significant endometrial or cervical disease.
  • METHODS: A retrospective chart review was conducted of 343 postmenopausal women with endometrial fluid collection on pelvic sonography.
  • Medical records were reviewed to identify women who underwent an evaluation of the endometrium with endometrial biopsy, hysteroscopy, or hysterectomy after the sonographic examination.
  • Clinical and sonographic characteristics were compared between women with diagnoses of cervical or endometrial cancer or hyperplasia (nonbenign group) and women with benign conditions (benign group).
  • RESULTS: The endometrium was significantly thicker in the nonbenign group compared with the benign group (mean +/- SD, 9.9 +/- 7.4 versus 5.9 +/- 4.1 mm; P = .016).
  • None of the patients with adenocarcinoma of the endometrium had endometrial thickness of 3 mm or less, but 2 with endocervical cancer did.
  • Echogenic fluid in the endometrial cavity was significantly more likely to be found in the nonbenign group compared with the benign group (45.8% versus 4.8%; P < .01).
  • Multivariate logistic regression analysis revealed that echogenic fluid in the endometrial cavity was the only significant risk factor for nonbenign conditions (odds ratio, 10.94; 95% confidence interval, 2.67-44.84; P < .01).
  • CONCLUSIONS: Postmenopausal women with endometrial fluid collection on sonography should undergo endometrial sampling if the endometrial lining is thicker than 3 mm or the endometrial fluid is echogenic.
  • If the lining is 3 mm or less and the endometrial fluid is clear, endometrial sampling is not necessary, but we recommend endocervical sampling to rule out endocervical cancer.
  • [MeSH-major] Endometrium. Postmenopause. Uterine Cervical Diseases / ultrasonography
  • [MeSH-minor] Body Fluids. Female. Humans. Middle Aged. Retrospective Studies. Risk Factors. Uterine Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239648.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Oztekin O, Soylu F, Yigit S, Sarica E: Uterine tumor resembling ovarian sex cord tumors in a patient using tamoxifen: report of a case and review of literature. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine tumor resembling ovarian sex cord tumors in a patient using tamoxifen: report of a case and review of literature.
  • Increasing number of uterine malignancies have been reported in breast cancer patients using tamoxifen.
  • Most of these are endometrial adenocarcinomas.
  • However, only a few cases of endometrial stromal sarcomas have been reported to be linked with tamoxifen usage.
  • A 58-year-old postmenopausal women who had been using tamoxifen for 4 years after a surgery for breast cancer is presented with chronic pelvic pain.
  • Preoperative investigations were indicative of a uterine myoma so that a standard total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed.
  • Postoperative histologic diagnosis was a uterine tumor resembling ovarian sex cord tumors, which is an exceedingly rare entity itself.
  • The present case is the first designated diagnosis of this rare tumor, with a possible association of tamoxifen usage.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Sex Cord-Gonadal Stromal Tumors / diagnosis. Tamoxifen / adverse effects. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Postmenopause

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884388.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


86. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Rabbitt C, Chi DS, Soslow RA, Abu-Rustum NR: Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. Am J Obstet Gynecol; 2010 Mar;202(3):278.e1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology.
  • OBJECTIVE: The purpose of this study was to determine posthysterectomy pathologic findings in patients with a preoperative endometrial sampling diagnosis of International Federation of Gynecology and Obstetrics (FIGO) grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia (CAH).
  • STUDY DESIGN: We reviewed 1423 consecutive cases of endometrial cancer to identify cases with a preoperative endometrial biopsy that demonstrated FIGO grade 1 endometrial adenocarcinoma.
  • Final uterine pathologic findings were grouped into low- and high-risk based on FIGO and Gynecologic Oncology Group criteria.
  • CONCLUSION: An endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of CAH is more likely to correlate with final posthysterectomy grade than a diagnosis not arising with a background of CAH.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20022581.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, Makedos G: Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet; 2006 May;274(2):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer.
  • OBJECTIVE: The purpose of the study is to evaluate whether surgery followed by radiotherapy in high-risk patients of early stage endometrial cancer can be replaced by formal surgical staging.
  • Cancer-related survival and recurrence-free survival (RFS) were the endpoints of the analysis.
  • STUDY DESIGN: One hundred and eighteen patients with endometrioid endometrial adenocarcinoma between 1996-2003 were reviewed.
  • The recurrence rate in low-risk patients was 2.7%, the cancer-related survival 97.5% and RFS 97%, while in the high-risk patients 12%, 93% and 88%, respectively.
  • Comparing the therapeutic modalities (staging lymphadenectomy vs. postoperative irradiation) in the high-risk group the cancer-related survival and RFS was not differed (P=0.70, P=0.90, respectively).
  • CONCLUSION: According our results the low-risk patients of early stage endometrial adenocarcinoma had excellent survival with minimal intervention.
  • The cancer-related survival and RFS in high-risk patients concerning the therapeutic modalities were comparable.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Lymph Node Excision

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518607.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Kim KH, Kim JM, Choi YL, Shin YK, Lee HC, Seong IO, Kim BK, Chae SW, Chung YS, Kim SH: Expression of sonic hedgehog signaling molecules in normal, hyperplastic and carcinomatous endometrium. Pathol Int; 2009 May;59(5):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of sonic hedgehog signaling molecules in normal, hyperplastic and carcinomatous endometrium.
  • The aim of the present study was to determine the expression profile of the hedgehog (Hh) signaling molecules in normal, hyperplastic, and carcinomatous uterine endometrium.
  • For this purpose, 271 endometrial tissue samples, (62 of normal endometrium, 127 of endometrial hyperplasias, and 82 endometrial adenocarcinomas) were studied using antibodies recognizing Hh-related signaling proteins, such as, sonic hedgehog (Shh), Patched (PTCH), Smoothened (Smo), Suppressor of fused [Su(Fu)], Gli-1, Gli-2, and Gli-3 by immunohistochemistry.
  • In the normal endometrium, the expression of Hh signaling molecules was generally downregulated except for Su(Fu), Gli-2, and Shh.
  • Overall expression of Hh signaling molecules increased in hyperplastic endometrium; in particular, PTCH and Smo were significantly highly expressed in complex and atypical hyperplasia.
  • In carcinoma samples extensive alterations were observed in the expression pattern of the signaling molecules.
  • Nuclear Gli-2, cytoplasmic Gli-3, and Su(Fu) were overexpressed, whereas Shh, PTCH, and Smo expression were significantly reduced compared with the hyperplastic endometrium.
  • The results suggest that the alteration of Hh signaling may be implicated in tumorigenesis of the endometrium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Hedgehog Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432668.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / GLI3 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Repressor Proteins; 0 / SHH protein, human; 0 / SMO protein, human; 0 / SUFU protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


89. Hirabayashi K, Yasuda M, Kajiwara H, Nakamura N, Sato S, Nishijima Y, Mikami M, Osamura RY: Clear cell adenocarcinoma arising from adenomyosis. Int J Gynecol Pathol; 2009 May;28(3):262-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising from adenomyosis.
  • An elevated level of CA125 in the blood favored a diagnosis of malignant uterine body tumor, but was not confirmed by endometrial cytology and biopsy.
  • Resection of the uterus revealed a solid whitish tumor in the myometrium that was diagnosed as clear cell adenocarcinoma (CCA) arising from adenomyosis.
  • There were transitions between endometrial epithelium of adenomyosis, noninvasive CCA, and invasive CCA.
  • Immunohistochemical expression of hepatocyte nuclear factor-1beta supported the diagnosis of CCA.
  • Malignant tumor arising from adenomyosis should be considered as a differential diagnosis when the serum level of tumor markers such as CA125 is high and when the tumor is intramyometrial.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. CA-125 Antigen / blood. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620944.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


90. Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, Bifulco G, Simonetti S, Orlando P, Insabato L, Nappi C, Di Spiezio Sardo A, Di Marzo V, Iuvone T: The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology; 2010 Mar;151(3):921-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma.
  • The endocannabinoid system plays protective roles against the growth and the spreading of several types of carcinomas.
  • Because estrogens regulate this system both in physiological states and cancer, in this paper we evaluated its involvement in endometrial carcinoma, a well-known estrogen-dependent tumor.
  • To test whether the endocannabinoid system is expressed in endometrial cancer, tissue samples were collected both from 18 patients undergoing surgical treatment for endometrial adenocarcinoma and 16 healthy age-matched controls, and treated for Western blot and immunohistochemical analysis.
  • To evaluate the physiological role of the endocannabinoid system, a human endometrial cancer cell-line (AN3CA) was used and transiently transfected with a plasmid containing the cDNA for the endocannabinoid receptor CB(2).
  • In human endometrial carcinoma biopsies the expression of CB(2) receptor and the levels of its ligand, 2-arachidonoylglycerol increased, whereas monoacylglycerol lipase, an enzyme responsible for 2-arachidonoylglycerol degradation, was down-regulated.
  • Immunohistochemical analysis revealed that CB(2) was overexpressed only in malignant endometrial cells.
  • In conclusion, the endocannabinoid system seems to play an important role in human endometrial carcinoma, and modulation of CB(2) activity/expression may account for a tumor-suppressive effect.
  • [MeSH-major] Arachidonic Acids / metabolism. Carcinoma / metabolism. Endometrial Neoplasms / metabolism. Glycerides / metabolism. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Adult. Biopsy. Cell Line, Tumor. Down-Regulation. Endocannabinoids. Endometrium / pathology. Female. Humans. Middle Aged. Monoacylglycerol Lipases / metabolism. Up-Regulation

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133454.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Endocannabinoids; 0 / Glycerides; 0 / Receptor, Cannabinoid, CB2; 53847-30-6 / 2-arachidonylglycerol; EC 3.1.1.23 / Monoacylglycerol Lipases
  •  go-up   go-down


91. Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL, Gatter KC, Tumour and Angiogenesis Research Group: Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol; 2006 May;19(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis.
  • Vascular endothelial growth factor (VEGF) is a potent angiogenic factor for many malignant neoplasms exerting its function through activation of specific membrane receptors, that is, KDR/flk-1, residing in endothelial cells.
  • Several recent reports indicate that VEGF receptors are also expressed in cancer cells, suggesting that specific VEGF-originated cancer cell reactions may parallel the endothelial response.
  • Using a novel monoclonal antibody, recognizing the activated (phosphorylated) form of the KDR receptor (pKDR), we assessed the expression of pKDR in normal and malignant endometrium.
  • A strong and consistent cytoplasmic and nuclear pKDR expression was noted in the normally cycling endometrium, including epithelial, stromal and endothelial cells, suggesting a role in the normal menstrual cycle.
  • Approximately, one-third of the 70 stage I endometrioid adenocarcinomas analysed exhibited an intense cytoplasmic and nuclear pKDR expression in both cancer cells and peritumoral vessels.
  • It was noted that such pKDR reactivity in cancer cells was related directly to VEGF, VEGF/KDR complexes and HIF1alpha (hypoxia inducible factor 1alpha) expression.
  • It is concluded that the VEGF/KDR pathway is activated in both normally cycling and malignant endometrium, suggestive of an important role in the biology of this tissue.
  • The unfavourable prognosis that VEGF confers to endometrial adenocarcinomas could be attributed to its angiogenic activity, but also to a direct effect on cancer cells through an autocrine VEGF/KDR loop.
  • [MeSH-major] Endometrial Neoplasms / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Signal Transduction. Vascular Endothelial Growth Factor A / physiology. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Endometrium / chemistry. Endometrium / pathology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Phosphoproteins / metabolism. Phosphorylation. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557278.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Phosphoproteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


92. Feng YZ, Shiozawa T, Horiuchi A, Shih HC, Miyamoto T, Kashima H, Suzuki A, Nikaido T, Konishi I: Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch; 2005 Nov;447(5):816-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.
  • To further elucidate the significance of p53 mutation in endometrial carcinoma, we investigated it in endometrioid-type endometrial carcinomas showing intratumoral heterogeneous p53 expression.
  • The p53 mutation in exons 5-8 in 54 cases of endometrial carcinoma showing immunohistochemical expression of p53 was examined using microdissected tissue DNAs.
  • Of the 54 p53-positive endometrial carcinomas, 23 (43%) had p53 mutation with a tendency in histologically higher grade tumors.
  • These results suggest that p53 mutation is a late event and plays an important role in the acquisition of malignant potentials in endometrioid-type endometrial adenocarcinomas.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cyclin A / metabolism. Endometrial Neoplasms / metabolism. Genes, p53. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 2000 Jul 14;300(3):503-18 [10884347.001]
  • [Cites] Exp Cell Res. 1994 Jan;210(1):94-101 [8270002.001]
  • [Cites] J Pathol. 1997 Nov;183(3):318-24 [9422988.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):232-9 [11400116.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S40-52 [10396300.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] J Neurooncol. 1994;22(3):255-9 [7760104.001]
  • [Cites] Cell. 1994 Nov 18;79(4):551-5 [7954821.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):562-7 [8761370.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3674-8 [1319827.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Genes Dev. 1995 May 15;9(10):1149-63 [7758941.001]
  • [Cites] Eur J Cancer. 1994;30A(4):504-8 [8018409.001]
  • [Cites] Cancer. 1995 Jul 1;76(1):72-8 [8630879.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1622-7 [1540970.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):453-9 [10600306.001]
  • [Cites] Mod Pathol. 1995 May;8(4):441-5 [7567946.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):321-9 [8625241.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17 (2):129-34 [9553809.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2034-40 [8634996.001]
  • [Cites] Hum Pathol. 2003 May;34(5):471-8 [12792921.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2250-6 [9404701.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1050-5 [8892589.001]
  • [Cites] Int J Gynecol Pathol. 1997 Oct;16(4):348-53 [9421074.001]
  • (PMID = 16021509.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin A; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


93. Healy KA, Carney KJ, Osunkoya AO: Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature. ScientificWorldJournal; 2010;10:1714-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature.
  • Endometriosis is characterized by endometrial-like tissue outside the uterus, primarily on the pelvic peritoneum, ovaries, and rectovaginal septum, and, in rare cases, within the urinary tract (1-3%).
  • Although endometriosis is a benign condition, malignant transformation of endometriosis is a well-described phenomenon.
  • A case of endometrioid adenocarcinoma in the native ureter of a postmenopausal renal transplant patient presented with painless gross hematuria and hydroureteronephrosis.
  • Endoscopic biopsies of the native left ureteral mass showed endometrioid adenocarcinoma, grade II-III.
  • Final pathology confirmed endometrioid adenocarcinoma, grade II-III, arising in a background of endometriosis with negative perirectal lymph nodes.
  • This case of ureteral endometrioid adenocarcinoma highlights the importance of obtaining a careful history and maintaining a high index of suspicion for malignant degeneration, especially in the context of hyperestrogenism.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Kidney Transplantation. Ureter / pathology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842317.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


94. Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC, Yu MH: Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol; 2009 Dec;135(12):1665-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation analysis of SFRP genes family in cervical adenocarcinoma.
  • Recently, we have shown that secreted frizzled-related proteins (SFRPs) are frequently methylated in cervical squamous cell carcinoma (SCC).
  • Here, we want to further investigate the methylation status and function of SFRPs in adenocarcinoma of uterine cervix.
  • METHODS: The methylation status of SFRPs was assessed in 23 adenocarcinomas (AC), and 45 normal control swabs by methylation-specific polymerase chain reaction and bisulfite sequencing.
  • Then, we used reexpression of SFRP5 in cervical cancer cell lines, HeLa3rd and CaSki, to study the role of SFRP5 in cervical adenocarcinoma by colony formation and invasion assays.
  • RESULTS: The frequency of SFRP genes promoter hypermethylation in adenocarcinoma of cervix samples was 52.2% (12/23), 82.6% (19/23), 65.2% (15/23), and 73.9% (17/23), for SFRP1, SFRP2, SFRP4, and SFRP5, respectively.
  • The frequency of SFRP1, SFRP2, SFRP4, and SFRP5 promoter methylation in adenocarcinoma was significantly higher than in normal control samples (P < 0.001).
  • CONCLUSIONS: Our data suggest that promoter hypermethylation of SFRPs is associated with cervical adenocarcinoma, which could be used for molecular screening of cervical adenocarcinoma in the future.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Membrane Proteins / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1992 Jan;44(1):71-8 [1730429.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):991-8 [18356147.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6770-5 [9192640.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2007 Dec;47(6):504-7 [17991118.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):86-90 [11452312.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Mar;36(3):233-41 [12557223.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3396-400 [15161694.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):579-90 [16795071.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Mar;65(1):45-53 [8706956.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16 [16609023.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Apr;94(2):151-2 [9109947.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1028-35 [17443492.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2981-4 [12912945.001]
  • [Cites] J Med Screen. 1997;4(1):40-3 [9200062.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] J Pathol. 2002 Jan;196(1):1-7 [11748635.001]
  • [Cites] Int J Gynecol Cancer. 2002 Mar-Apr;12(2):171-6 [11975676.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):810-9 [10819705.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):301-6 [19038436.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3546-51 [10097073.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1258-64 [15693030.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):161-7 [18398837.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):67-70 [9892187.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):629-35 [17097722.001]
  • (PMID = 19513747.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / SFRP1 protein, human; 0 / SFRP5 protein, human
  •  go-up   go-down


95. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, Chi DS, Soslow RA, Abu-Rustum NR: Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol; 2008 Nov;111(2):244-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma.
  • OBJECTIVE: To evaluate the ability of a preoperative diagnosis of FIGO grade 1 endometrial adenocarcinoma and intraoperative depth of myoinvasion (DOI) to predict low-risk (LR) and high-risk (HR) final uterine pathology.
  • METHODS: We reviewed 1423 consecutive cases of endometrial cancer treated at our institution between 1/1/93 and 5/31/06 to identify cases with a preoperative endometrial biopsy demonstrating FIGO grade 1 endometrial adenocarcinoma.
  • Final uterine pathologic findings were grouped into low- and high-risk.
  • HR final uterine pathology was seen in 86 (18.5%) cases.
  • CONCLUSIONS: Preoperative FIGO grade 1 diagnosis correlates with final post-hysterectomy grade in 85% of cases.
  • The rate of HR uterine pathology based on preoperative grade 1 alone is 18.5%.
  • Frozen section may help further stratify for the risk of final HR uterine pathology but is not entirely accurate.
  • The rate of HR uterine pathology is 4% if no cancer or myoinvasion is identified on frozen section and 18% if myoinvasion up to 50% is identified.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752842.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, Gold MA, McMeekin DS, Modesitt S, Cooper AL, Powell MA, Mutch DG, Nag S, Alvarez RD, Cohn DE: Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):886-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.
  • The objective of this study was to evaluate the treatment outcomes and risk factors of women with surgical stage I endometrial adenocarcinoma who were initially treated with surgery alone and subsequently developed isolated vaginal recurrences.
  • Patients with surgical stage I endometrial adenocarcinoma diagnosed from 1975 to 2002 were identified from tumor registry databases at seven institutions.
  • Sixty-nine women with surgical stage I endometrial cancer with isolated vaginal recurrences were identified.
  • The majority of isolated vaginal recurrences in women with surgical stage I endometrial cancer can be successfully salvaged with radiation therapy, further questioning the role of adjuvant therapy for patients with uterine-confined endometrial cancer at the time of initial diagnosis.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309665.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


97. Marshburn PB, Zhang J, Bahrani-Mostafavi Z, Matthews ML, White J, Hurst BS: Variant progesterone receptor mRNAs are co-expressed with the wild-type progesterone receptor mRNA in human endometrium during all phases of the menstrual cycle. Mol Hum Reprod; 2005 Nov;11(11):809-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant progesterone receptor mRNAs are co-expressed with the wild-type progesterone receptor mRNA in human endometrium during all phases of the menstrual cycle.
  • Progesterone receptor (PR) variant mRNAs in human endometrium could encode proteins with the potential to alter progesterone action in states of normal and abnormal endometrial development.
  • We have assessed the expression levels of mRNA for the wild-type PR and splice variants of PR mRNA lacking exon 4 (del-4 PR), exon 6 (del-6 PR), exons 4 and 6 (del-4&6 PR), and part of exon 4 (del-p4 PR) or part of exon 6 (del-p6 PR) in the human endometrium throughout menstrual cycle development.
  • Eighty-eight endometrial specimens (47 proliferative, 41 secretory) were collected from patients undergoing hysterectomy for benign gynaecologic causes.
  • Measurements by RT-PCR indicated that mRNAs for wild-type PR, and splice variants del-4 PR, del-6 PR, del-4&6 PR, del-p6 PR, and a novel del-p4 PR were detected in all endometrial specimens throughout the menstrual cycle.
  • Higher levels of wild-type PR and all PR variant mRNAs were found in the early and mid-proliferative endometrial phases than in secretory endometrium.
  • The relative expression of mRNA for all PR variants compared to wild-type PR mRNA, however, did not change through all stages of endometrial development.
  • Future studies will determine if the expression profile of PR variant mRNAs will be different in the endometrium of patients with infertility, recurrent pregnancy loss, or endometrial adenocarcinoma.
  • [MeSH-major] Endometrium / physiology. Gene Expression Regulation. Genetic Variation. Menstrual Cycle / physiology. RNA, Messenger / genetics. Receptors, Progesterone / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339776.001).
  • [ISSN] 1360-9947
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, Progesterone
  •  go-up   go-down


98. Bidziński M, Dańska-Bidzińska A, Derlatka P, Sobiczewski P, Gmyrek L, Jońska-Gmyrek J, Panek G: [Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer]. Ginekol Pol; 2007 Jun;78(6):471-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer].
  • INTRODUCTION: The risk of endometrial cancer recurrence is estimated to be about 20%.
  • MATERIAL AND METHODS: Between the year 2001 and 2003, 203 from 243 patients with endometrial cancer underwent surgery.
  • The following histoclinical factors were taken into account: age, number of deliveries, BMI, use of estrogens, co-morbidity, histoclinical type, grading and the spread of cancer inside the uterus, pelvis and retroperitoneal space.
  • The most important factors in the multivariate analysis were: type of histology (serous or clear cell cancer) and lymph node involvement.
  • CONCLUSION: In patients with endometrial cancer the risk of recurrences increases when lymph node metastases are recognized.
  • Four times higher recurrence risk is observed in serous or clear cell cancer, comparing with other histological types.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Women's Health
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adult. Cystadenocarcinoma, Papillary / secondary. Cystadenocarcinoma, Papillary / surgery. Female. Genital Neoplasms, Female / secondary. Genital Neoplasms, Female / surgery. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Poland. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899704.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


99. Brown YK, Knowles S, Fiorello CV, Camus MS, Howerth EW: Pathology in practice. Morphologic diagnosis: Uterine adenocarcinoma with metastasis to the lungs, diaphragm, spleen, mesentery, and cecum. J Am Vet Med Assoc; 2010 Dec 1;237(11):1257-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology in practice. Morphologic diagnosis: Uterine adenocarcinoma with metastasis to the lungs, diaphragm, spleen, mesentery, and cecum.
  • [MeSH-major] Adenocarcinoma / veterinary. Rabbits. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118010.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Chen YH, Li XP, Wang Y, Wang JL, Wei LH: [Regulation of Bub1 mRNA expression in endometrial carcinoma Ishikawa cells by estrogen and paclitaxel]. Zhonghua Fu Chan Ke Za Zhi; 2010 Sep;45(9):686-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regulation of Bub1 mRNA expression in endometrial carcinoma Ishikawa cells by estrogen and paclitaxel].
  • OBJECTIVE: To explore the regulation of Bub1 mRNA expression in endometrial carcinoma cells by estrogen and paclitaxel.
  • METHODS: The high differentiated endometrial adenocarcinoma cells (Ishikawa cell line) were cultured in DMED/F12 supplemented with 10% fetal bovine serum (FBS) or phenol red-free DMED/F12 supplemented with 5% dextran-charcoal FBS (dcFBS).
  • [MeSH-major] Endometrial Neoplasms / metabolism. Estradiol / pharmacology. Paclitaxel / pharmacology. Protein-Serine-Threonine Kinases / metabolism

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092550.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement